

Enteral and Oral Nutritional Supplements

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Enteral and Oral Nutritional Supplements	1
Summary	1
Definitions	3
Medical Necessity Criteria for Clinical Review	4
General Medical Necessity Criteria	4
Medical Necessity Criteria for Subsequent Clinical Review	9
Subsequent Medical Necessity Criteria	9
Experimental or Investigational / Not Medically Necessary	10
Applicable Billing Codes	10
References	56
Clinical Guideline Revision / History Information	64

Summary

Enteral nutrition products, also known as medical foods or medically necessary foods, are specially formulated and processed foods intended for the dietary management of specific diseases or medical conditions. The use of enteral nutrition products has been shown to reduce hospital stays, complications, and mortality rates in patients with various medical conditions, including malnutrition, cancer, gastrointestinal disorders, neurological disorders, and metabolic disorders. Enteral and oral nutritional supplements are medically necessary only when used to prevent, evaluate, or treat illness or disease in accordance with evidence-based standards of care.

The Plan members who have difficulty ingesting or digesting food or who are at risk for malnutrition may be eligible for oral nutritional supplements.

To be considered a medical food or medically necessary food, a product must be labeled for the dietary management of a medical disorder, disease, or condition and labeled to be used under medical supervision. These products provide essential nutrients to individuals who have limited or impaired capacity to ingest, digest, absorb, or metabolize regular food or certain nutrients, or who have other medically determined nutrient requirements that cannot be achieved by modifying their normal diet alone.

- For more information about medical foods or medically necessary foods, please refer to:
 - The FDA's "Frequently Asked Questions About Medical Foods; Third Edition" guidance document: <https://www.fda.gov/media/97726/download>.
 - The National Library of Medicine's DailyMed database (<https://dailymed.nlm.nih.gov>) which contains up-to-date labeling information for medical foods or medically necessary foods.

Please note: The inclusion or exclusion of a medical food, or medically necessary food, product in these resources does not imply or guarantee coverage or reimbursement by the Plan.

Coverage of medical foods is subject to:

- *The terms and conditions of the member's policy at the time of service*
- *Applicable state and federal laws.*
- *The medical necessity criteria outlined in this policy.*
- *Product-specific clinical guidelines where applicable.*

Enteral nutrition products come in various forms, including nutritionally complete formulas, nutritionally incomplete formulas, formulas for metabolic disorders, and oral rehydration products. They are primarily administered through the gastrointestinal tract, either orally or via a feeding tube or catheter that delivers nutrients beyond the oral cavity, directly to the stomach, or even beyond the stomach by infusing calories directly to the small bowel.

Medical foods, or medically necessary foods, are typically obtained from hospitals, clinics, and other medical facilities, but certain specialized nutritional supplement products may be covered by the Plan's Pharmacy benefit. This includes products necessary for malabsorption disorders, renal dysfunction, tube feeding formulas, and lactose-free infant formulas, as well as other specialized products. Some medical foods, or medically necessary foods, may also be obtained through a prescription from a Pharmacy and covered by the Plan's Pharmacy benefit (i.e., supplied by a pharmacy provider upon the prescription of a physician within the scope of his or her practice). Additional Clinical Policy may apply for coverage via the Pharmacy benefit, such as:

- Nutritional Supplements – Infant Formulas
- Nutritional Supplements – Malabsorption Products
- Nutritional Supplements – Renal Dysfunction Products
- Nutritional Supplements – Tube Feeding Products

NOTE: All oral nutritional supplementation must be prescribed by a licensed provider and eligibility and cost of coverage are based on the member's Schedule of Benefits and Certificate of Coverage.

Definitions

“Elemental and Semi-Elemental Products” refers to products that contain partially or fully broken down macronutrients.

“Enteral Nutrition” is the administration of nutrition through the gastrointestinal (GI) tract. This can be done through:

1. the oral cavity, as in traditional eating
2. a nasogastric or orogastric tube (tube placed through the nose or mouth into the stomach)
3. a gastric or gastro-jejunal feeding tube (placed percutaneously directly into the stomach or small intestine, bypassing the oral cavity and esophagus)

“Failure to Thrive (FTT)” is a term applicable to children younger than 2 years old, and defined using WHO growth charts which can identify weight gain issues including:

1. Children weighing less than the 2nd percentile for gestation-corrected age and sex when plotted on the appropriate growth chart on more than one occasion (Note: Special charts for patients with genetic syndromes or prematurity may be applicable); *or*
2. Children with weight-for-length Z-score falling below 2; *or*
3. Decreased growth velocity of weight gain compared to growth in length.

“Food Additives” are products available over-the-counter that are ingested in addition to a regular diet. Examples include calorie supplements, digestive aids, fiber supplements, minerals, protein supplements, thickeners, and vitamins.

“Medical foods or Medically Necessary Foods” are a specific category of food products that are formulated to be consumed or administered enterally (through the digestive system) under the supervision of a physician for the dietary management of a specific disease or condition for which distinctive nutritional requirements have been established based on recognized scientific principles. Medical foods are intended to meet the distinctive nutritional needs of patients with certain medical or metabolic conditions who cannot meet their nutritional requirements through a normal diet alone. They are distinguished from the broader category of foods for special dietary use and from foods that make health claims by the requirement that medical foods are to be used under medical supervision.

“Oral Nutritional Supplements” are considered “medical foods” or “medically necessary foods” as defined by the FDA. They include metabolic formulas and modified low protein foods that are specially formulated and processed. They can be obtained in pharmacies or over-the-counter and are used for

patients with specific nutritional needs. Common trade brands include Ensure, Boost, Glucerna, Nepro, and Suplena.

“Parenteral Nutrition” refers to nutrition administered outside of the GI tract, such as intravenous feeding. It may be used when traditional enteral feeding is not possible due to obstructions, malabsorption, or congenital conditions. Parenteral nutrition is not discussed in this guideline.

“Poor Weight Gain” is a term applicable to children aged 2-18, and defined using the CDC Growth Charts and BMI-For-Age Charts which can identify weight gain issues including:

1. Abrupt weight loss following a period of normal growth along a well-established pattern of height and weight gain defined as crossing two or more major weight percentiles; *or*
2. Slow, steady weight gain below the fifth percentile of the NCHS growth curves; *or*
3. A growth curve proportionate to, but lower than, the child's expected height trajectory; *or*
4. Growth milestones that have been met but only with nutritional support consisting of high-calorie foods and/or nutritionally dense foods, where support with nutritional and calorie appropriate food is necessary.

Medical Necessity Criteria for Clinical Review

General Medical Necessity Criteria

The Plan considers Nutritional (Enteral) Products, Supplies, and Equipment medically necessary when ALL the following criteria are met (*as applicable*) below:

1. Recent documentation (within the last 6 months) of ALL of the following:
 - a. Medical nutritional product is prescribed by a licensed provider for the therapeutic treatment of a condition requiring specialized nutrients; *and*
 - b. Diagnosis or condition, including (*as applicable*) accurate diagnostic information pertaining to the underlying diagnosis or condition that resulted in the requirement for a nutritional product, such as:
 - i. Growth history and growth charts; *and*
 - ii. Height and weight; *and*
 - iii. Member's overall health status; *and*
 - iv. Other formulas tried and why they did not meet the member's needs; *and*
 - v. Why the member cannot be maintained on an age-appropriate diet; *and*
 - c. Goals and timelines on the medical plan of care; *and*
 - d. Specified quantity and duration of the prescription or order; *and*
 - e. Total caloric intake prescribed by the provider; *and*
 - f. For members who require tube feeding, documentation indicating that the member has a feeding tube in place; *AND*
2. The member is characterized by ONE of the following:
 - a. Member requires tube feedings and the following is met:

- i. A documented medical diagnosis that requires enteral nutrition products administered through a feeding tube should be provided; *or*
- b. Currently undergoing transition from parenteral or enteral diet (with tube feeding) to oral diet; *or*
- c. Member has severe swallowing or chewing difficulty due to ONE of the following:
 - i. Cancer in the mouth, throat, or esophagus; *or*
 - ii. Injury, trauma, surgery, or radiation therapy involving the head or neck; *or*
 - iii. Chronic neurological disorders; *or*
 - iv. Severe craniofacial anomalies; *or*
- d. Adult member 18 years of age and older (≥ 18) AND ONE of the following is met:
 - i. Documented chronic medical disease (e.g. HIV/AIDS, Crohn's disease, cystic fibrosis, etc) that is being appropriately treated AND inability to meet nutritional needs even with a dietary adjustment of regular or altered consistency (soft/pureed) foods; *or*
 - ii. Medical condition (acute or chronic) such as a metabolic, gastrointestinal, or gastroesophageal disorder that is being appropriately treated AND associated with an inability to meet nutritional needs with a dietary adjustment of regular or altered consistency foods (e.g., soft or pureed) AND ONE of the following:
 - 1. Involuntary weight loss of:
 - a. 10 percent or more of usual body weight within six months; *or*
 - b. 7.5 percent or more of usual body weight within three months; *or*
 - c. 5 percent or more of usual body weight in one month; *or*
 - 2. Body mass index less than 18.5 kg/m^2 ; *or*
 - iii. Multiple, severe food allergies which if left untreated will cause malnourishment, chronic physical disability, mental retardation or death; *or*
- e. Pediatric members under the age of 18 AND ONE of the following is met:
 - i. Members with inborn errors in metabolism, including but not limited to:
 - 1. Glutaric aciduria type I; *or*
 - 2. Homocystinuria; *or*
 - 3. Isovaleric acidemia; *or*
 - 4. Maple syrup urine disease; *or*
 - 5. Maternal phenylketonuria; *or*
 - 6. Methylmalonic acidemia; *or*
 - 7. Other disorders of leucine metabolism; *or*
 - 8. Phenylketonuria; *or*
 - 9. Propionic acidemia; *or*
 - 10. Tyrosinemia types I and II; *or*
 - 11. Urea cycle disorders; *or*
 - ii. Member has malnutrition or risk of malnutrition AND it is demonstrated by ONE of the following:

1. Allergic or eosinophilic enteritis (colitis/proctitis, esophagitis, gastroenteritis); *or*
 2. Allergy or hypersensitivity to cow or soy milk diagnosed through a formal food challenge; *or*
 3. Allergy to specific foods including food-induced anaphylaxis; *or*
 4. Cystic fibrosis with malabsorption; *or*
 5. Malabsorption unresponsive to standard age appropriate interventions when associated with failure to gain weight or meet established growth expectations; *or*
 6. Poor oral intake related to anatomic or motility related disorders of the GI tract; *or*
 7. Symptoms of malabsorption related to inflammatory disorders of the GI tract; *or*
- iii. Members aged 2-18 with poor weight gain, as defined above in "[Definitions](#)", that is unresponsive to standard age appropriate interventions; *or*
- iv. Members aged <2 years old with failure to thrive, as defined above in "[Definitions](#)", that is unresponsive to standard age appropriate interventions; *or*
- v. Pediatric members residing in Texas with nutritional deficiencies related to documented autism spectrum disorder; *or*

f. Pregnant Women with Hyperemesis Gravidarum AND ALL of the following is met:

- i. Condition is refractory first-line interventions, including both pharmacologic (e.g., antiemetics) and nonpharmacologic (e.g., dietary modifications) treatments; *and*
- ii. Member has experienced significant weight loss, defined as ONE of the following:
 1. Loss of more than 5% of pre-pregnancy weight; *or*
 2. Inability to tolerate sufficient oral intake to meet daily nutritional requirements; *and*
- iii. Member has been evaluated by a registered dietitian or qualified nutrition specialist, with a treatment plan that includes ongoing nutritional assessment and monitoring; *AND*

3. IF the requested product is for ONE of the following then the applicable criteria is met:

- a. Carbohydrate modular products administered orally or through a feeding tube, there must be documented evidence that the member is unable to meet caloric nutritional needs with the current use of an enteral nutrition product; *or*
- b. Diabetic products, the member must have documented evidence of BOTH of the following:
 - i. Diagnosis of hyperglycemia or diabetes; *and*
 - ii. HbA1c (A1c) value measured within six months of the authorization request; *or*

- b. Elemental or semi-elemental nutrition products, members must have documented evidence of ALL of the following:
 - i. Chronic intestinal malabsorption disease (lactose intolerance is excluded); *and*
 - ii. Be unable to absorb nutrients or tolerate intact protein in a way that cannot otherwise be medically managed or managed with alternative dietary options; *and*
 - iii. History of use of disease-specific or specialized nutrition products that have not been successful (unless medically contraindicated); *or*
- c. Hepatic products, the member must have documented results of liver function test measured within six months of the request; *or*
- d. Lipid (fat) modular products administered orally or through a feeding tube, the member must have documented evidence of ONE of the following diagnosis:
 - i. Inability to digest/absorb conventional fats; *or*
 - ii. Uncontrolled seizure disorder that cannot be otherwise managed (in cases of ketogenic diet); *or*
- e. Medical Foods Dispensed by Prescription, in the absence of product-specific clinical guideline or coverage criteria, documentation of ALL of the following:
 - i. The product is prescribed for the specific dietary management of a disease or condition with distinctive nutritional requirements; *and*
 - ii. The member has limited or impaired capacity to ingest, digest, absorb or metabolize normal foodstuffs or certain nutrients, or has medically determined special nutrient requirements; *and*
 - iii. Normal diet alone cannot meet the distinctive nutritional needs; *and*
 - iv. The safety and effectiveness of the product has been established for the member's age and disease or condition; *and*
 - v. The product is being used adjunctively with standard of care treatment options for the member's disease or condition, including drug therapy, non-drug, and supportive care.
- f. Protein modular products administered orally or through a feeding tube, there must be documented evidence that the member is unable to meet protein requirements with current use of a high protein enteral nutrition product; *or*
- g. Related supplies and equipment for nutritional products, provided that ALL of the following are met:
 - i. The criteria for nutritional products are met, as outlined in the Plan's clinical policy; *and*
 - ii. Medical necessity is documented for each requested item; *and*
 - iii. For additional feeding tubes, submitted documentation supports medical necessity, such as infection at gastrostomy site, leakage, or occlusion; *and*
 - iv. For enteral feeding pumps (with or without alarms), the member meets ANY of the following criteria:

1. Gravity or syringe feedings are not medically indicated; *or*
2. The member requires an administration rate of less than 100 ml/hr; *or*
3. The member requires night-time feedings; *or*
4. The member has a medical condition necessitating the use of an enteral feeding pump, such as blood glucose fluctuations, circulatory overload, dumping syndrome, reflux or aspiration, or severe diarrhea; *and*

- v. For a backpack or carrying case for a portable enteral feeding pump, documented evidence of BOTH of the following:
 1. The member requires enteral feedings lasting more than eight hours continuously, or the feeding intervals exceed the time the member must be away from home due to attending school or work, frequent medical appointments, or extensive physician-ordered outpatient therapies; *and*
 2. The member is ambulatory or uses a wheelchair that cannot support the use of a portable pump through other means, such as an IV pole; *or*

- h. Renal products, the member must have documented evidence of ONE of the following indicators measured within six months of the request:
 - i. Blood serum potassium (elevated); *or*
 - ii. BUN levels (>20mg/dl); *or*
 - iii. GFR < 60.

If the applicable criteria for prior authorization above are met, the requested Nutritional (Enteral) Products, Supplies, or Equipment will be authorized for the requested duration or according to the following durations, whichever is lesser:

- Extended Authorization (Up to 12 Months) may be granted when documentation confirms:
 - Permanent diagnosis/condition unlikely to resolve requiring ongoing nutritional support, such as:
 - Metabolic/Genetic Disorders:
 - Inborn errors of metabolism (e.g., PKU, MSUD).
 - Urea cycle disorders.
 - Other established metabolic disorders requiring specialized nutrition.
 - Anatomical/Structural Conditions:
 - Short bowel syndrome.
 - Permanent GI alterations (e.g., esophagectomy, gastrectomy).
 - Severe neurological conditions affecting feeding (e.g., cerebral palsy).
 - Chronic Malabsorption Conditions:
 - Cystic fibrosis with established nutritional regimen.
 - HIV/AIDS with stable nutritional needs.

- Other established malabsorption disorders.
- 90-Day Authorization may be granted when documentation indicates long-term but potentially modifiable conditions, including:
 - Permanent feeding tubes (gastrostomy or jejunostomy).
 - Members with cancer and on active treatment.
 - Post-surgical feeding support.
 - Failure to thrive with an established treatment plan.
 - Crohn's disease or ulcerative colitis in remission.
 - Stable renal disease requiring specialized nutrition.
- 30-Day Authorization will be granted for temporary or newly initiated support, including:
 - Temporary feeding tubes (nasogastric, nasoduodenal, nasojejunal).
 - New formula trials.
 - Initial post-hospital discharge orders.
 - Acute or unstable conditions:
 - Active inflammatory bowel disease flare.
 - Hyperemesis gravidarum.
 - Recent onset failure to thrive.
 - Post-operative nutrition initiation.
 - Acute illness recovery.
 - Any case not meeting criteria for longer authorization periods.

Continued Care

Medical Necessity Criteria for Subsequent Clinical Review

Subsequent Medical Necessity Criteria

The Plan considers Nutritional (Enteral) Products, Supplies, and Equipment medically necessary when ALL the following criteria are met (*as applicable*) below:

1. Documentation of ongoing medical necessity for prescribed nutritional products; *AND*
2. Evidence of treatment goal achievement or documented progress; *AND*
3. Current nutritional care plan; *AND*
4. Clinical assessment supporting continued need.

If approved, the requested nutritional products, supplies, or equipment will be authorized for the duration requested or for the longest appropriate duration based on the documented clinical condition, whichever is lesser:

- Up to 12 months for permanent conditions unlikely to resolve.
- Up to 90 days for long-term but potentially modifiable conditions.
- Up to 30 days for temporary or newly initiated support.

Note: Authorization will be granted for the longest appropriate duration according to the above guidelines based on the documented clinical condition.

Experimental or Investigational / Not Medically Necessary

- Over-the-counter products may not be covered, even if prescribed by a healthcare provider (refer to member's benefit plan for confirmation); *or*
- Medically necessary products must have a specific medical indication, not solely based on food preference or convenience; *or*
- Not medically necessary products may include, but are not limited to:
 - Baby food or standard infant formula; *or*
 - Breast milk; *or*
 - Enteral nutrition products used orally as a convenient alternative to preparing and/or consuming regular, solid, or pureed foods; *or*
 - Food thickeners; *or*
 - Gluten-free foods; *or*
 - High-protein powders or nutritional drinks; *or*
 - Items not categorized as medical foods or medically necessary foods; *or*
 - Low carbohydrate diet supplements; *or*
 - Non-prescription weight loss or weight gain products; *or*
 - Nutritional products for members who could be sustained on an age-appropriate diet; *or*
 - Products for assistance with weight loss; *or*
 - Regular food, including solid, semi-solid, and pureed foods; *or*
 - Relizorb (enzyme cartridge), considered experimental or investigational; *or*
 - Shakes, cereals, thickened products, puddings, bars, gels, and other non-liquid products.; *or*
 - Vitamins or minerals.

Applicable Billing Codes

Disclaimer

The codes for the treatments, procedures, and products listed below are provided for informational purposes only. Inclusion or exclusion of a code does not imply or guarantee coverage or reimbursement by the Plan. The actual coverage or non-coverage of services for an individual member will be determined by the terms and conditions of their policy at the time of service, as well as applicable state and federal law.

Please refer to the member's policy documents (such as the Certificate/Evidence of Coverage, Schedule of Benefits, or Plan Formulary) or contact the Plan to confirm coverage. The coverage of services is subject to the terms, conditions, and limitations of a member's policy.

Codes considered medically necessary if clinical criteria are met:

Table 1

CPT/HCPCS codes for medical foods considered medically necessary if criteria are met:

<i>Code</i>	<i>Description</i>
B4034	Enteral feeding supply kit; syringe fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape
B4035	Enteral feeding supply kit; pump fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape
B4036	Enteral feeding supply kit; gravity fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape
B4081	Nasogastric tubing with stylet
B4082	Nasogastric tubing without stylet
B4083	Stomach tube - Levine type
B4087	Gastrostomy/jejunostomy tube, standard, any material, any type, each
B4088	Gastrostomy/jejunostomy tube, low-profile, any material, any type, each
B4149	Enteral formula, manufactured blenderized natural foods with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
B4150	Enteral formula, nutritionally complete with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
B4152	Enteral formula, nutritionally complete, calorically dense (equal to or greater than 1.5 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
B4153	Enteral formula, nutritionally complete, hydrolyzed proteins (amino acids and peptide chain), includes fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
B4154	Enteral formula, nutritionally complete, for special metabolic needs, excludes inherited disease of metabolism, includes altered composition of proteins, fats, carbohydrates, vitamins and/or minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
B4155	Enteral formula, nutritionally incomplete/modular nutrients, includes specific nutrients, carbohydrates (e.g., glucose polymers), proteins/amino acids (e.g., glutamine, arginine), fat (e.g., medium chain triglycerides) or combination, administered through an enteral feeding tube, 100 calories = 1 unit

B4157	Enteral formula, nutritionally complete, for special metabolic needs for inherited disease of metabolism, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
B4158	Enteral formula, for pediatrics, nutritionally complete with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber and/or iron, administered through an enteral feeding tube, 100 calories = 1 unit
B4159	Enteral formula, for pediatrics, nutritionally complete soy based with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber and/or iron, administered through an enteral feeding tube, 100 calories = 1 unit
B4160	Enteral formula, for pediatrics, nutritionally complete calorically dense (equal to or greater than 0.7 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
B4161	Enteral formula, for pediatrics, hydrolyzed/amino acids and peptide chain proteins, includes fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
B4162	Enteral formula, for pediatrics, special metabolic needs for inherited disease of metabolism, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
B9002	Enteral nutrition infusion pump, any type
B9998	NOC for enteral supplies
S9432	Medical foods for non inborn errors of metabolism
S9433	Medical food nutritionally complete, administered orally, providing 100% of nutritional intake
S9434	Modified solid food supplements for inborn errors of metabolism
S9435	Medical foods for inborn errors of metabolism

Table 2	
ICD-10 diagnosis codes considered medically necessary for medical foods with Table 1 if criteria are met:	
C00.0	Malignant neoplasm of external upper lip
C00.1	Malignant neoplasm of external lower lip
C00.2	Malignant neoplasm of external lip, unspecified

C00.3	Malignant neoplasm of upper lip, inner aspect
C00.4	Malignant neoplasm of lower lip, inner aspect
C00.5	Malignant neoplasm of lip, unspecified, inner aspect
C00.6	Malignant neoplasm of commissure of lip, unspecified
C00.8	Malignant neoplasm of overlapping sites of lip
C00.9	Malignant neoplasm of lip, unspecified
<u>C01</u>	Malignant neoplasm of base of tongue
<u>C02</u>	Malignant neoplasm of other and unspecified parts of tongue
C02.0	Malignant neoplasm of dorsal surface of tongue
C02.1	Malignant neoplasm of border of tongue
C02.2	Malignant neoplasm of ventral surface of tongue
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified
C02.4	Malignant neoplasm of lingual tonsil
C02.8	Malignant neoplasm of overlapping sites of tongue
C02.9	Malignant neoplasm of tongue, unspecified
C03	Malignant neoplasm of gum
C03.0	Malignant neoplasm of upper gum
C03.1	Malignant neoplasm of lower gum
C03.9	Malignant neoplasm of gum, unspecified
C04	Malignant neoplasm of floor of mouth
C04.0	Malignant neoplasm of anterior floor of mouth
C04.1	Malignant neoplasm of lateral floor of mouth
C04.8	Malignant neoplasm of overlapping sites of floor of mouth
C04.9	Malignant neoplasm of floor of mouth, unspecified
C05	Malignant neoplasm of palate
C05.0	Malignant neoplasm of hard palate
C05.1	Malignant neoplasm of soft palate
C05.2	Malignant neoplasm of uvula
C05.8	Malignant neoplasm of overlapping sites of palate
C05.9	Malignant neoplasm of palate, unspecified
C06	Malignant neoplasm of other and unspecified parts of mouth
C06.0	Malignant neoplasm of cheek mucosa
C06.1	Malignant neoplasm of vestibule of mouth
C06.2	Malignant neoplasm of retromolar area

C06.8	Malignant neoplasm of overlapping sites of other and unspecified parts of mouth
C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth
C06.89	Malignant neoplasm of overlapping sites of other parts of mouth
C06.9	Malignant neoplasm of mouth, unspecified
C07	Malignant neoplasm of parotid gland
C08	Malignant neoplasm of other and unspecified major salivary glands
C08.0	Malignant neoplasm of submandibular gland
C08.1	Malignant neoplasm of sublingual gland
C08.9	Malignant neoplasm of major salivary gland, unspecified
C09	Malignant neoplasm of tonsil
C09.0	Malignant neoplasm of tonsillar fossa
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)
C09.8	Malignant neoplasm of overlapping sites of tonsil
C09.9	Malignant neoplasm of tonsil, unspecified
C10	Malignant neoplasm of oropharynx
C10.0	Malignant neoplasm of vallecula
C10.1	Malignant neoplasm of anterior surface of epiglottis
C10.2	Malignant neoplasm of lateral wall of oropharynx
C10.3	Malignant neoplasm of posterior wall of oropharynx
C10.4	Malignant neoplasm of branchial cleft
C10.8	Malignant neoplasm of overlapping sites of oropharynx
C10.9	Malignant neoplasm of oropharynx, unspecified
C11	Malignant neoplasm of nasopharynx
C11.0	Malignant neoplasm of superior wall of nasopharynx
C11.1	Malignant neoplasm of posterior wall of nasopharynx
C11.2	Malignant neoplasm of lateral wall of nasopharynx
C11.3	Malignant neoplasm of anterior wall of nasopharynx
C11.8	Malignant neoplasm of overlapping sites of nasopharynx
C11.9	Malignant neoplasm of nasopharynx, unspecified
C12	Malignant neoplasm of pyriform sinus
C13	Malignant neoplasm of hypopharynx
C13.0	Malignant neoplasm of postcricoid region
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect
C13.2	Malignant neoplasm of posterior wall of hypopharynx

C13.8	Malignant neoplasm of overlapping sites of hypopharynx
C13.9	Malignant neoplasm of hypopharynx, unspecified
C14	Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx
C14.0	Malignant neoplasm of pharynx, unspecified
C14.2	Malignant neoplasm of Waldeyer's ring
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx
C15	Malignant neoplasm of esophagus
C15.3	Malignant neoplasm of upper third of esophagus
C15.4	Malignant neoplasm of middle third of esophagus
C15.5	Malignant neoplasm of lower third of esophagus
C15.8	Malignant neoplasm of overlapping sites of esophagus
C15.9	Malignant neoplasm of esophagus, unspecified
C16	Malignant neoplasm of stomach
C16.0	Malignant neoplasm of cardia
C16.1	Malignant neoplasm of fundus of stomach
C16.2	Malignant neoplasm of body of stomach
C16.3	Malignant neoplasm of pyloric antrum
C16.4	Malignant neoplasm of pylorus
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified
C16.8	Malignant neoplasm of overlapping sites of stomach
C16.9	Malignant neoplasm of stomach, unspecified
C17	Malignant neoplasm of small intestine
C17.0	Malignant neoplasm of duodenum
C17.1	Malignant neoplasm of jejunum
C17.2	Malignant neoplasm of ileum
C17.3	Meckel's diverticulum, malignant
C17.8	Malignant neoplasm of overlapping sites of small intestine
C17.9	Malignant neoplasm of small intestine, unspecified
C18	Malignant neoplasm of colon
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.3	Malignant neoplasm of hepatic flexure

C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21	Malignant neoplasm of anus and anal canal
C21.0	Malignant neoplasm of anus, unspecified
C21.1	Malignant neoplasm of anal canal
C21.2	Malignant neoplasm of cloacogenic zone
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C76.0	Malignant neoplasm of head, face and neck
D81.810	Biotinidase deficiency
D81.818	Other biotin-dependent carboxylase deficiency
E40	Kwashiorkor
E41	Nutritional marasmus
E42	Marasmic kwashiorkor
E43	Unspecified severe protein-calorie malnutrition
E44.0	Moderate protein-calorie malnutrition
E44.1	Mild protein-calorie malnutrition
E45	Retarded development following protein-calorie malnutrition
E46	Unspecified protein-calorie malnutrition
E70.0	Classical phenylketonuria
E70.1	Other hyperphenylalaninemia
E70.20	Disorder of tyrosine metabolism, unspecified
E70.21	Tyrosinemia
E70.29	Other disorders of tyrosine metabolism
E70.30	Albinism, unspecified
E70.31	Ocular albinism
E70.310	X-linked ocular albinism
E70.311	Autosomal recessive ocular albinism
E70.318	Other ocular albinism

E70.319	Ocular albinism, unspecified
E70.32	Oculocutaneous albinism
E70.320	Tyrosinase negative oculocutaneous albinism
E70.321	Tyrosinase positive oculocutaneous albinism
E70.328	Other oculocutaneous albinism
E70.329	Oculocutaneous albinism, unspecified
E70.33	Albinism with hematologic abnormality
E70.330	Chediak-Higashi syndrome
E70.331	Hermansky-Pudlak syndrome
E70.338	Other albinism with hematologic abnormality
E70.339	Albinism with hematologic abnormality, unspecified
E70.39	Other specified albinism
E70.4	Disorders of histidine metabolism
E70.40	Disorders of histidine metabolism, unspecified
E70.41	Histidinemia
E70.49	Other disorders of histidine metabolism
E70.5	Disorders of tryptophan metabolism
E70.81	Aromatic L-amino acid decarboxylase deficiency
E70.89	Other disorders of aromatic amino-acid metabolism
E70.9	Disorder of aromatic amino-acid metabolism, unspecified
E71.0	Maple-syrup-urine disease
E71.110	Isovaleric acidemia
E71.111	3-methylglutaconic aciduria
E71.118	Other branched-chain organic acidurias
E71.120	Methylmalonic acidemia
E71.121	Propionic acidemia
E71.128	Other disorders of propionate metabolism
E71.19	Other disorders of branched-chain amino-acid metabolism
E71.2	Disorder of branched-chain amino-acid metabolism, unspecified
E71.30	Disorder of fatty-acid metabolism, unspecified
E71.310	Long chain/very long chain acyl CoA dehydrogenase deficiency
E71.311	Medium chain acyl CoA dehydrogenase deficiency
E71.312	Short chain acyl CoA dehydrogenase deficiency
E71.313	Glutaric aciduria type II

E71.314	Muscle carnitine palmitoyltransferase deficiency
E71.318	Other disorders of fatty-acid oxidation
E71.32	Disorders of ketone metabolism
E71.39	Other disorders of fatty-acid metabolism
E71.40	Disorders of carnitine metabolism, unspecified
E71.41	Primary carnitine deficiency
E71.42	Carnitine deficiency due to inborn errors of metabolism
E71.448	Other secondary carnitine deficiency
E71.50	Peroxisomal disorder, unspecified
E71.520	Childhood cerebral X-linked adrenoleukodystrophy
E71.53	Other group 2 peroxisomal disorders
E71.541	Zellweger-like syndrome
E71.542	Other group 3 peroxisomal disorders
E71.548	Other peroxisomal disorders
E72.00	Disorders of amino-acid transport, unspecified
E72.01	Cystinuria
E72.02	Hartnup's disease
E72.03	Lowe's syndrome
E72.04	Cystinosis
E72.09	Other disorders of amino-acid transport
E72.10	Disorders of sulfur-bearing amino-acid metabolism, unspecified
E72.11	Homocystinuria
E72.12	Methylenetetrahydrofolate reductase deficiency
E72.19	Other disorders of sulfur-bearing amino-acid metabolism
E72.20	Disorder of urea cycle metabolism, unspecified
E72.21	Argininemia
E72.22	Arginosuccinic aciduria
E72.23	Citrullinemia
E72.29	Other disorders of urea cycle metabolism
E72.3	Disorders of lysine and hydroxylysine metabolism
E72.4	Disorders of ornithine metabolism
E72.50	Disorder of glycine metabolism, unspecified
E72.51	Non-ketotic hyperglycinemia
E72.52	Trimethylaminuria

E72.53	Primary hyperoxaluria
E72.530	Primary hyperoxaluria, type 1
E72.538	Other specified primary hyperoxaluria
E72.539	Primary hyperoxaluria, unspecified
E72.54	Secondary hyperoxaluria
E72.540	Dietary hyperoxaluria
E72.541	Enteric hyperoxaluria
E72.548	Other secondary hyperoxaluria
E72.549	Secondary hyperoxaluria, unspecified
E72.59	Other disorders of glycine metabolism
E72.81	Disorders of gamma aminobutyric acid metabolism
E72.89	Other specified disorders of amino-acid metabolism
E72.9	Disorder of amino-acid metabolism, unspecified
E74.00	Glycogen storage disease, unspecified
E74.01	von Gierke disease
E74.02	Pompe disease
E74.03	Cori disease
E74.04	McArdle disease
E74.05	Lysosome-associated membrane protein 2 [LAMP2] deficiency
E74.09	Other glycogen storage disease
E74.1	Disorders of fructose metabolism
E74.10	Disorder of fructose metabolism, unspecified
E74.11	Essential fructosuria
E74.12	Hereditary fructose intolerance
E74.19	Other disorders of fructose metabolism
E74.2	Disorders of galactose metabolism
E74.20	Disorders of galactose metabolism, unspecified
E74.21	Galactosemia
E74.29	Other disorders of galactose metabolism
E74.3	Other disorders of intestinal carbohydrate absorption
E74.31	Sucrase-isomaltase deficiency
E74.39	Other disorders of intestinal carbohydrate absorption
E74.4	Disorders of pyruvate metabolism and gluconeogenesis
E74.8	Other specified disorders of carbohydrate metabolism

E74.81	Disorders of glucose transport, not elsewhere classified
E74.810	Glucose transporter protein type 1 deficiency
E74.818	Other disorders of glucose transport
E74.819	Disorders of glucose transport, unspecified
E74.82	Disorders of citrate metabolism
E74.820	SLC13A5 Citrate Transporter Disorder
E74.829	Other disorders of citrate metabolism
E74.89	Other specified disorders of carbohydrate metabolism
E74.9	Disorder of carbohydrate metabolism, unspecified
E75.00	GM2 gangliosidosis, unspecified
E75.01	Sandhoff disease
E75.02	Tay-Sachs disease
E75.09	Other GM2 gangliosidosis
E75.1	Other and unspecified gangliosidosis
E75.10	Unspecified gangliosidosis
E75.11	Mucolipidosis IV
E75.19	Other gangliosidosis
E75.2	Other sphingolipidosis
E75.21	Fabry (-Anderson) disease
E75.22	Gaucher disease
E75.23	Krabbe disease
E75.24	Niemann-Pick disease
E75.240	Niemann-Pick disease type A
E75.241	Niemann-Pick disease type B
E75.242	Niemann-Pick disease type C
E75.243	Niemann-Pick disease type D
E75.244	Niemann-Pick disease type A/B
E75.248	Other Niemann-Pick disease
E75.249	Niemann-Pick disease, unspecified
E75.25	Metachromatic leukodystrophy
E75.26	Sulfatase deficiency
E75.27	Pelizaeus-Merzbacher disease
E75.28	Canavan disease
E75.29	Other sphingolipidosis

E75.3	Sphingolipidosis, unspecified
E75.4	Neuronal ceroid lipofuscinosis
E75.5	Other lipid storage disorders
E75.6	Lipid storage disorder, unspecified
E76.01	Hurler's syndrome
E76.02	Hurler-Scheie syndrome
E76.03	Scheie's syndrome
E76.1	Mucopolysaccharidosis, type II
E76.2	Other mucopolysaccharidoses
E76.21	Morquio mucopolysaccharidoses
E76.210	Morquio A mucopolysaccharidoses
E76.211	Morquio B mucopolysaccharidoses
E76.219	Morquio mucopolysaccharidoses, unspecified
E76.22	Sanfilippo mucopolysaccharidoses
E76.29	Other mucopolysaccharidoses
E76.3	Mucopolysaccharidosis, unspecified
E76.8	Other disorders of glucosaminoglycan metabolism
E76.9	Glucosaminoglycan metabolism disorder, unspecified
E77.0	Defects in post-translational modification of lysosomal enzymes
E77.1	Defects in glycoprotein degradation
E77.8	Other disorders of glycoprotein metabolism
E77.9	Disorder of glycoprotein metabolism, unspecified
E78.72	Smith-Lemli-Opitz syndrome
E84	Cystic fibrosis
E84.0	Cystic fibrosis with pulmonary manifestations
E84.1	Cystic fibrosis with intestinal manifestations
E84.11	Meconium ileus in cystic fibrosis
E84.19	Cystic fibrosis with other intestinal manifestations
E84.8	Cystic fibrosis with other manifestations
E84.9	Cystic fibrosis, unspecified
E88.4	Mitochondrial metabolism disorders
E88.40	Mitochondrial metabolism disorder, unspecified
E88.41	MELAS syndrome
E88.42	MERRF syndrome
E88.43	Disorders of mitochondrial tRNA synthetases

E88.49	Other mitochondrial metabolism disorders
F01.50	Vascular dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
F01.51	Vascular dementia, unspecified severity, with behavioral disturbance
F01.511	Vascular dementia, unspecified severity, with agitation
F01.518	Vascular dementia, unspecified severity, with other behavioral disturbance
F01.52	Vascular dementia, unspecified severity, with psychotic disturbance
F01.53	Vascular dementia, unspecified severity, with mood disturbance
F01.54	Vascular dementia, unspecified severity, with anxiety
F01.A	Vascular dementia, mild
F01.A0	Vascular dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
F01.A1	Vascular dementia, mild, with behavioral disturbance
F01.A11	Vascular dementia, mild, with agitation
F01.A18	Vascular dementia, mild, with other behavioral disturbance
F01.A2	Vascular dementia, mild, with psychotic disturbance
F01.A3	Vascular dementia, mild, with mood disturbance
F01.A4	Vascular dementia, mild, with anxiety
F01.B	Vascular dementia, moderate
F01.B0	Vascular dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
F01.B1	Vascular dementia, moderate, with behavioral disturbance
F01.B11	Vascular dementia, moderate, with agitation
F01.B18	Vascular dementia, moderate, with other behavioral disturbance
F01.B2	Vascular dementia, moderate, with psychotic disturbance
F01.B3	Vascular dementia, moderate, with mood disturbance
F01.B4	Vascular dementia, moderate, with anxiety
F01.C	Vascular dementia, severe
F01.C0	Vascular dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
F01.C1	Vascular dementia, severe, with behavioral disturbance
F01.C11	Vascular dementia, severe, with agitation
F01.C18	Vascular dementia, severe, with other behavioral disturbance
F01.C2	Vascular dementia, severe, with psychotic disturbance
F01.C3	Vascular dementia, severe, with mood disturbance
F01.C4	Vascular dementia, severe, with anxiety
F02	Dementia in other diseases classified elsewhere
F02.8	Dementia in other diseases classified elsewhere, unspecified severity

F02.80	Dementia in other diseases classified elsewhere, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
F02.81	Dementia in other diseases classified elsewhere, unspecified severity, with behavioral disturbance
F02.811	Dementia in other diseases classified elsewhere, unspecified severity, with agitation
F02.818	Dementia in other diseases classified elsewhere, unspecified severity, with other behavioral disturbance
F02.82	Dementia in other diseases classified elsewhere, unspecified severity, with psychotic disturbance
F02.83	Dementia in other diseases classified elsewhere, unspecified severity, with mood disturbance
F02.84	Dementia in other diseases classified elsewhere, unspecified severity, with anxiety
F02.A	Dementia in other diseases classified elsewhere, mild
F02.A0	Dementia in other diseases classified elsewhere, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
F02.A1	Dementia in other diseases classified elsewhere, mild, with behavioral disturbance
F02.A11	Dementia in other diseases classified elsewhere, mild, with agitation
F02.A18	Dementia in other diseases classified elsewhere, mild, with other behavioral disturbance
F02.A2	Dementia in other diseases classified elsewhere, mild, with psychotic disturbance
F02.A3	Dementia in other diseases classified elsewhere, mild, with mood disturbance
F02.A4	Dementia in other diseases classified elsewhere, mild, with anxiety
F02.B	Dementia in other diseases classified elsewhere, moderate
F02.B0	Dementia in other diseases classified elsewhere, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
F02.B1	Dementia in other diseases classified elsewhere, moderate, with behavioral disturbance
F02.B11	Dementia in other diseases classified elsewhere, moderate, with agitation
F02.B18	Dementia in other diseases classified elsewhere, moderate, with other behavioral disturbance
F02.B2	Dementia in other diseases classified elsewhere, moderate, with psychotic disturbance
F02.B3	Dementia in other diseases classified elsewhere, moderate, with mood disturbance
F02.B4	Dementia in other diseases classified elsewhere, moderate, with anxiety
F02.C	Dementia in other diseases classified elsewhere, severe
F02.C0	Dementia in other diseases classified elsewhere, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
F02.C1	Dementia in other diseases classified elsewhere, severe, with behavioral disturbance
F02.C11	Dementia in other diseases classified elsewhere, severe, with agitation

F02.C18	Dementia in other diseases classified elsewhere, severe, with other behavioral disturbance
F02.C2	Dementia in other diseases classified elsewhere, severe, with psychotic disturbance
F02.C3	Dementia in other diseases classified elsewhere, severe, with mood disturbance
F02.C4	Dementia in other diseases classified elsewhere, severe, with anxiety
F03	Unspecified dementia
F03.9	Unspecified dementia, unspecified severity
F03.90	Unspecified dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
F03.91	Unspecified dementia, unspecified severity, with behavioral disturbance
F03.911	Unspecified dementia, unspecified severity, with agitation
F03.918	Unspecified dementia, unspecified severity, with other behavioral disturbance
F03.92	Unspecified dementia, unspecified severity, with psychotic disturbance
F03.93	Unspecified dementia, unspecified severity, with mood disturbance
F03.94	Unspecified dementia, unspecified severity, with anxiety
F03.A	Unspecified dementia, mild
F03.A0	Unspecified dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
F03.A1	Unspecified dementia, mild, with behavioral disturbance
F03.A11	Unspecified dementia, mild, with agitation
F03.A18	Unspecified dementia, mild, with other behavioral disturbance
F03.A2	Unspecified dementia, mild, with psychotic disturbance
F03.A3	Unspecified dementia, mild, with mood disturbance
F03.A4	Unspecified dementia, mild, with anxiety
F03.B	Unspecified dementia, moderate
F03.B0	Unspecified dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
F03.B1	Unspecified dementia, moderate, with behavioral disturbance
F03.B11	Unspecified dementia, moderate, with agitation
F03.B18	Unspecified dementia, moderate, with other behavioral disturbance
F03.B2	Unspecified dementia, moderate, with psychotic disturbance
F03.B3	Unspecified dementia, moderate, with mood disturbance
F03.B4	Unspecified dementia, moderate, with anxiety
F03.C	Unspecified dementia, severe
F03.C0	Unspecified dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety
F03.C1	Unspecified dementia, severe, with behavioral disturbance
F03.C11	Unspecified dementia, severe, with agitation

F03.C18	Unspecified dementia, severe, with other behavioral disturbance
F03.C2	Unspecified dementia, severe, with psychotic disturbance
F03.C3	Unspecified dementia, severe, with mood disturbance
F03.C4	Unspecified dementia, severe, with anxiety
F04	Amnestic disorder due to known physiological condition
F05	Delirium due to known physiological condition
F06	Other mental disorders due to known physiological condition
F06.0	Psychotic disorder with hallucinations due to known physiological condition
F06.1	Catatonic disorder due to known physiological condition
F06.2	Psychotic disorder with delusions due to known physiological condition
F06.3	Mood disorder due to known physiological condition
F06.30	Mood disorder due to known physiological condition, unspecified
F06.31	Mood disorder due to known physiological condition with depressive features
F06.32	Mood disorder due to known physiological condition with major depressive-like episode
F06.33	Mood disorder due to known physiological condition with manic features
F06.34	Mood disorder due to known physiological condition with mixed features
F06.4	Anxiety disorder due to known physiological condition
F06.7	Mild neurocognitive disorder due to known physiological condition
F06.70	Mild neurocognitive disorder due to known physiological condition without behavioral disturbance
F06.71	Mild neurocognitive disorder due to known physiological condition with behavioral disturbance
F06.8	Other specified mental disorders due to known physiological condition
F07	Personality and behavioral disorders due to known physiological condition
F07.0	Personality change due to known physiological condition
F07.8	Other personality and behavioral disorders due to known physiological condition
F07.81	Postconcussion syndrome
F07.89	Other personality and behavioral disorders due to known physiological condition
F07.9	Unspecified personality and behavioral disorder due to known physiological condition
F09	Unspecified mental disorder due to known physiological condition
F10	Alcohol related disorders
F10.1	Alcohol abuse
F10.10	Alcohol abuse, uncomplicated
F10.11	Alcohol abuse, in remission
F10.12	Alcohol abuse with intoxication
F10.120	Alcohol abuse with intoxication, uncomplicated

F10.121	Alcohol abuse with intoxication delirium
F10.129	Alcohol abuse with intoxication, unspecified
F10.13	Alcohol abuse, with withdrawal
F10.130	Alcohol abuse with withdrawal, uncomplicated
F10.131	Alcohol abuse with withdrawal delirium
F10.132	Alcohol abuse with withdrawal with perceptual disturbance
F10.139	Alcohol abuse with withdrawal, unspecified
F10.14	Alcohol abuse with alcohol-induced mood disorder
F10.15	Alcohol abuse with alcohol-induced psychotic disorder
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified
F10.18	Alcohol abuse with other alcohol-induced disorders
F10.180	Alcohol abuse with alcohol-induced anxiety disorder
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction
F10.182	Alcohol abuse with alcohol-induced sleep disorder
F10.188	Alcohol abuse with other alcohol-induced disorder
F10.19	Alcohol abuse with unspecified alcohol-induced disorder
F10.2	Alcohol dependence
F10.20	Alcohol dependence, uncomplicated
F10.21	Alcohol dependence, in remission
F10.22	Alcohol dependence with intoxication
F10.220	Alcohol dependence with intoxication, uncomplicated
F10.221	Alcohol dependence with intoxication delirium
F10.229	Alcohol dependence with intoxication, unspecified
F10.23	Alcohol dependence with withdrawal
F10.230	Alcohol dependence with withdrawal, uncomplicated
F10.231	Alcohol dependence with withdrawal delirium
F10.232	Alcohol dependence with withdrawal with perceptual disturbance
F10.239	Alcohol dependence with withdrawal, unspecified
F10.24	Alcohol dependence with alcohol-induced mood disorder
F10.25	Alcohol dependence with alcohol-induced psychotic disorder
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder
F10.27	Alcohol dependence with alcohol-induced persisting dementia

F10.28	Alcohol dependence with other alcohol-induced disorders
F10.280	Alcohol dependence with alcohol-induced anxiety disorder
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction
F10.282	Alcohol dependence with alcohol-induced sleep disorder
F10.288	Alcohol dependence with other alcohol-induced disorder
F10.29	Alcohol dependence with unspecified alcohol-induced disorder
F10.9	Alcohol use, unspecified
F10.90	Alcohol use, unspecified, uncomplicated
F10.91	Alcohol use, unspecified, in remission
F10.92	Alcohol use, unspecified with intoxication
F10.920	Alcohol use, unspecified with intoxication, uncomplicated
F10.921	Alcohol use, unspecified with intoxication delirium
F10.929	Alcohol use, unspecified with intoxication, unspecified
F10.93	Alcohol use, unspecified with withdrawal
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated
F10.931	Alcohol use, unspecified with withdrawal delirium
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance
F10.939	Alcohol use, unspecified with withdrawal, unspecified
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder
F10.95	Alcohol use, unspecified with alcohol-induced psychotic disorder
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia
F10.98	Alcohol use, unspecified with other alcohol-induced disorders
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder
F10.988	Alcohol use, unspecified with other alcohol-induced disorder
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder
F11	Opioid related disorders
F11.1	Opioid abuse
F11.10	Opioid abuse, uncomplicated
F11.11	Opioid abuse, in remission
F11.12	Opioid abuse with intoxication

F11.120	Opioid abuse with intoxication, uncomplicated
F11.121	Opioid abuse with intoxication delirium
F11.122	Opioid abuse with intoxication with perceptual disturbance
F11.129	Opioid abuse with intoxication, unspecified
F11.13	Opioid abuse with withdrawal
F11.14	Opioid abuse with opioid-induced mood disorder
F11.15	Opioid abuse with opioid-induced psychotic disorder
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified
F11.18	Opioid abuse with other opioid-induced disorder
F11.181	Opioid abuse with opioid-induced sexual dysfunction
F11.182	Opioid abuse with opioid-induced sleep disorder
F11.188	Opioid abuse with other opioid-induced disorder
F11.19	Opioid abuse with unspecified opioid-induced disorder
F11.2	Opioid dependence
F11.20	Opioid dependence, uncomplicated
F11.21	Opioid dependence, in remission
F11.22	Opioid dependence with intoxication
F11.220	Opioid dependence with intoxication, uncomplicated
F11.221	Opioid dependence with intoxication delirium
F11.222	Opioid dependence with intoxication with perceptual disturbance
F11.229	Opioid dependence with intoxication, unspecified
F11.23	Opioid dependence with withdrawal
F11.24	Opioid dependence with opioid-induced mood disorder
F11.25	Opioid dependence with opioid-induced psychotic disorder
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified
F11.28	Opioid dependence with other opioid-induced disorder
F11.281	Opioid dependence with opioid-induced sexual dysfunction
F11.282	Opioid dependence with opioid-induced sleep disorder
F11.288	Opioid dependence with other opioid-induced disorder
F11.29	Opioid dependence with unspecified opioid-induced disorder
F11.9	Opioid use, unspecified
F11.90	Opioid use, unspecified, uncomplicated
F11.91	Opioid use, unspecified, in remission

F11.92	Opioid use, unspecified with intoxication
F11.920	Opioid use, unspecified with intoxication, uncomplicated
F11.921	Opioid use, unspecified with intoxication delirium
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance
F11.929	Opioid use, unspecified with intoxication, unspecified
F11.93	Opioid use, unspecified with withdrawal
F11.94	Opioid use, unspecified with opioid-induced mood disorder
F11.95	Opioid use, unspecified with opioid-induced psychotic disorder
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified
F11.98	Opioid use, unspecified with other specified opioid-induced disorder
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction
F11.982	Opioid use, unspecified with opioid-induced sleep disorder
F11.988	Opioid use, unspecified with other opioid-induced disorder
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder
F12	Cannabis related disorders
F12.1	Cannabis abuse
F12.10	Cannabis abuse, uncomplicated
F12.11	Cannabis abuse, in remission
F12.12	Cannabis abuse with intoxication
F12.120	Cannabis abuse with intoxication, uncomplicated
F12.121	Cannabis abuse with intoxication delirium
F12.122	Cannabis abuse with intoxication with perceptual disturbance
F12.129	Cannabis abuse with intoxication, unspecified
F12.13	Cannabis abuse with withdrawal
F12.15	Cannabis abuse with psychotic disorder
F12.150	Cannabis abuse with psychotic disorder with delusions
F12.151	Cannabis abuse with psychotic disorder with hallucinations
F12.159	Cannabis abuse with psychotic disorder, unspecified
F12.18	Cannabis abuse with other cannabis-induced disorder
F12.180	Cannabis abuse with cannabis-induced anxiety disorder
F12.188	Cannabis abuse with other cannabis-induced disorder
F12.19	Cannabis abuse with unspecified cannabis-induced disorder
F12.2	Cannabis dependence
F12.20	Cannabis dependence, uncomplicated
F12.21	Cannabis dependence, in remission

F12.22	Cannabis dependence with intoxication
F12.220	Cannabis dependence with intoxication, uncomplicated
F12.221	Cannabis dependence with intoxication delirium
F12.222	Cannabis dependence with intoxication with perceptual disturbance
F12.229	Cannabis dependence with intoxication, unspecified
F12.23	Cannabis dependence with withdrawal
F12.25	Cannabis dependence with psychotic disorder
F12.250	Cannabis dependence with psychotic disorder with delusions
F12.251	Cannabis dependence with psychotic disorder with hallucinations
F12.259	Cannabis dependence with psychotic disorder, unspecified
F12.28	Cannabis dependence with other cannabis-induced disorder
F12.280	Cannabis dependence with cannabis-induced anxiety disorder
F12.288	Cannabis dependence with other cannabis-induced disorder
F12.29	Cannabis dependence with unspecified cannabis-induced disorder
F12.9	Cannabis use, unspecified
F12.90	Cannabis use, unspecified, uncomplicated
F12.91	Cannabis use, unspecified, in remission
F12.92	Cannabis use, unspecified with intoxication
F12.920	Cannabis use, unspecified with intoxication, uncomplicated
F12.921	Cannabis use, unspecified with intoxication delirium
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance
F12.929	Cannabis use, unspecified with intoxication, unspecified
F12.93	Cannabis use, unspecified with withdrawal
F12.95	Cannabis use, unspecified with psychotic disorder
F12.950	Cannabis use, unspecified with psychotic disorder with delusions
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified
F12.98	Cannabis use, unspecified with other cannabis-induced disorder
F12.980	Cannabis use, unspecified with anxiety disorder
F12.988	Cannabis use, unspecified with other cannabis-induced disorder
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder
F13	Sedative, hypnotic, or anxiolytic related disorders
F13.1	Sedative, hypnotic or anxiolytic-related abuse
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission
F13.12	Sedative, hypnotic or anxiolytic abuse with intoxication
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated

F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified
F13.13	Sedative, hypnotic or anxiolytic abuse with withdrawal
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder
F13.15	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified
F13.18	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorders
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder
F13.2	Sedative, hypnotic or anxiolytic-related dependence
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated
F13.21	Sedative, hypnotic or anxiolytic dependence, in remission
F13.22	Sedative, hypnotic or anxiolytic dependence with intoxication
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified
F13.23	Sedative, hypnotic or anxiolytic dependence with withdrawal
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance

F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder
F13.25	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia
F13.28	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorders
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder
F13.9	Sedative, hypnotic or anxiolytic-related use, unspecified
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated
F13.91	Sedative, hypnotic or anxiolytic use, unspecified, in remission
F13.92	Sedative, hypnotic or anxiolytic use, unspecified with intoxication
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified
F13.93	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder

F13.95	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia
F13.98	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorders
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder
F14	Cocaine related disorders
F14.1	Cocaine abuse
F14.10	Cocaine abuse, uncomplicated
F14.11	Cocaine abuse, in remission
F14.12	Cocaine abuse with intoxication
F14.120	Cocaine abuse with intoxication, uncomplicated
F14.121	Cocaine abuse with intoxication with delirium
F14.122	Cocaine abuse with intoxication with perceptual disturbance
F14.129	Cocaine abuse with intoxication, unspecified
F14.13	Cocaine abuse, unspecified with withdrawal
F14.14	Cocaine abuse with cocaine-induced mood disorder
F14.15	Cocaine abuse with cocaine-induced psychotic disorder
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified
F14.18	Cocaine abuse with other cocaine-induced disorder
F14.180	Cocaine abuse with cocaine-induced anxiety disorder

F14.181	Cocaine abuse with cocaine-induced sexual dysfunction
F14.182	Cocaine abuse with cocaine-induced sleep disorder
F14.188	Cocaine abuse with other cocaine-induced disorder
F14.19	Cocaine abuse with unspecified cocaine-induced disorder
F14.2	Cocaine dependence
F14.20	Cocaine dependence, uncomplicated
F14.21	Cocaine dependence, in remission
F14.22	Cocaine dependence with intoxication
F14.220	Cocaine dependence with intoxication, uncomplicated
F14.221	Cocaine dependence with intoxication delirium
F14.222	Cocaine dependence with intoxication with perceptual disturbance
F14.229	Cocaine dependence with intoxication, unspecified
F14.23	Cocaine dependence with withdrawal
F14.24	Cocaine dependence with cocaine-induced mood disorder
F14.25	Cocaine dependence with cocaine-induced psychotic disorder
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified
F14.28	Cocaine dependence with other cocaine-induced disorder
F14.280	Cocaine dependence with cocaine-induced anxiety disorder
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction
F14.282	Cocaine dependence with cocaine-induced sleep disorder
F14.288	Cocaine dependence with other cocaine-induced disorder
F14.29	Cocaine dependence with unspecified cocaine-induced disorder
F14.9	Cocaine use, unspecified
F14.90	Cocaine use, unspecified, uncomplicated
F14.91	Cocaine use, unspecified, in remission
F14.92	Cocaine use, unspecified with intoxication
F14.920	Cocaine use, unspecified with intoxication, uncomplicated
F14.921	Cocaine use, unspecified with intoxication delirium
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance
F14.929	Cocaine use, unspecified with intoxication, unspecified
F14.93	Cocaine use, unspecified with withdrawal
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder
F14.95	Cocaine use, unspecified with cocaine-induced psychotic disorder
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions

F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified
F14.98	Cocaine use, unspecified with other specified cocaine-induced disorder
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder
F14.988	Cocaine use, unspecified with other cocaine-induced disorder
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder
F15	Other stimulant related disorders
F15.1	Other stimulant abuse
F15.10	Other stimulant abuse, uncomplicated
F15.11	Other stimulant abuse, in remission
F15.12	Other stimulant abuse with intoxication
F15.120	Other stimulant abuse with intoxication, uncomplicated
F15.121	Other stimulant abuse with intoxication delirium
F15.122	Other stimulant abuse with intoxication with perceptual disturbance
F15.129	Other stimulant abuse with intoxication, unspecified
F15.13	Other stimulant abuse with withdrawal
F15.14	Other stimulant abuse with stimulant-induced mood disorder
F15.15	Other stimulant abuse with stimulant-induced psychotic disorder
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified
F15.18	Other stimulant abuse with other stimulant-induced disorder
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction
F15.182	Other stimulant abuse with stimulant-induced sleep disorder
F15.188	Other stimulant abuse with other stimulant-induced disorder
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder
F15.2	Other stimulant dependence
F15.20	Other stimulant dependence, uncomplicated
F15.21	Other stimulant dependence, in remission
F15.22	Other stimulant dependence with intoxication
F15.220	Other stimulant dependence with intoxication, uncomplicated
F15.221	Other stimulant dependence with intoxication delirium
F15.222	Other stimulant dependence with intoxication with perceptual disturbance

F15.229	Other stimulant dependence with intoxication, unspecified
F15.23	Other stimulant dependence with withdrawal
F15.24	Other stimulant dependence with stimulant-induced mood disorder
F15.25	Other stimulant dependence with stimulant-induced psychotic disorder
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified
F15.28	Other stimulant dependence with other stimulant-induced disorder
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction
F15.282	Other stimulant dependence with stimulant-induced sleep disorder
F15.288	Other stimulant dependence with other stimulant-induced disorder
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder
F15.9	Other stimulant use, unspecified
F15.90	Other stimulant use, unspecified, uncomplicated
F15.91	Other stimulant use, unspecified, in remission
F15.92	Other stimulant use, unspecified with intoxication
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated
F15.921	Other stimulant use, unspecified with intoxication delirium
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance
F15.929	Other stimulant use, unspecified with intoxication, unspecified
F15.93	Other stimulant use, unspecified with withdrawal
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder
F15.95	Other stimulant use, unspecified with stimulant-induced psychotic disorder
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified
F15.98	Other stimulant use, unspecified with other stimulant-induced disorder
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder

F16	Hallucinogen related disorders
F16.1	Hallucinogen abuse
F16.10	Hallucinogen abuse, uncomplicated
F16.11	Hallucinogen abuse, in remission
F16.12	Hallucinogen abuse with intoxication
F16.120	Hallucinogen abuse with intoxication, uncomplicated
F16.121	Hallucinogen abuse with intoxication with delirium
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance
F16.129	Hallucinogen abuse with intoxication, unspecified
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder
F16.15	Hallucinogen abuse with hallucinogen-induced psychotic disorder
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified
F16.18	Hallucinogen abuse with other hallucinogen-induced disorder
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder
F16.2	Hallucinogen dependence
F16.20	Hallucinogen dependence, uncomplicated
F16.21	Hallucinogen dependence, in remission
F16.22	Hallucinogen dependence with intoxication
F16.220	Hallucinogen dependence with intoxication, uncomplicated
F16.221	Hallucinogen dependence with intoxication with delirium
F16.229	Hallucinogen dependence with intoxication, unspecified
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder
F16.25	Hallucinogen dependence with hallucinogen-induced psychotic disorder
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified
F16.28	Hallucinogen dependence with other hallucinogen-induced disorder
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)

F16.288	Hallucinogen dependence with other hallucinogen-induced disorder
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder
F16.9	Hallucinogen use, unspecified
F16.90	Hallucinogen use, unspecified, uncomplicated
F16.91	Hallucinogen use, unspecified, in remission
F16.92	Hallucinogen use, unspecified with intoxication
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated
F16.921	Hallucinogen use, unspecified with intoxication with delirium
F16.929	Hallucinogen use, unspecified with intoxication, unspecified
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder
F16.95	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified
F16.98	Hallucinogen use, unspecified with other specified hallucinogen-induced disorder
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder
F17	Nicotine dependence
F17.2	Nicotine dependence
F17.20	Nicotine dependence, unspecified
F17.200	Nicotine dependence, unspecified, uncomplicated
F17.201	Nicotine dependence, unspecified, in remission
F17.203	Nicotine dependence unspecified, with withdrawal
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders
F17.21	Nicotine dependence, cigarettes
F17.210	Nicotine dependence, cigarettes, uncomplicated
F17.211	Nicotine dependence, cigarettes, in remission
F17.213	Nicotine dependence, cigarettes, with withdrawal
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders
F17.22	Nicotine dependence, chewing tobacco

F17.220	Nicotine dependence, chewing tobacco, uncomplicated
F17.221	Nicotine dependence, chewing tobacco, in remission
F17.223	Nicotine dependence, chewing tobacco, with withdrawal
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders
F17.29	Nicotine dependence, other tobacco product
F17.290	Nicotine dependence, other tobacco product, uncomplicated
F17.291	Nicotine dependence, other tobacco product, in remission
F17.293	Nicotine dependence, other tobacco product, with withdrawal
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders
F18	Inhalant related disorders
F18.1	Inhalant abuse
F18.10	Inhalant abuse, uncomplicated
F18.11	Inhalant abuse, in remission
F18.12	Inhalant abuse with intoxication
F18.120	Inhalant abuse with intoxication, uncomplicated
F18.121	Inhalant abuse with intoxication delirium
F18.129	Inhalant abuse with intoxication, unspecified
F18.14	Inhalant abuse with inhalant-induced mood disorder
F18.15	Inhalant abuse with inhalant-induced psychotic disorder
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified
F18.17	Inhalant abuse with inhalant-induced dementia
F18.18	Inhalant abuse with other inhalant-induced disorders
F18.180	Inhalant abuse with inhalant-induced anxiety disorder
F18.188	Inhalant abuse with other inhalant-induced disorder
F18.19	Inhalant abuse with unspecified inhalant-induced disorder
F18.2	Inhalant dependence
F18.20	Inhalant dependence, uncomplicated
F18.21	Inhalant dependence, in remission
F18.22	Inhalant dependence with intoxication
F18.220	Inhalant dependence with intoxication, uncomplicated
F18.221	Inhalant dependence with intoxication delirium

F18.229	Inhalant dependence with intoxication, unspecified
F18.24	Inhalant dependence with inhalant-induced mood disorder
F18.25	Inhalant dependence with inhalant-induced psychotic disorder
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified
F18.27	Inhalant dependence with inhalant-induced dementia
F18.28	Inhalant dependence with other inhalant-induced disorders
F18.280	Inhalant dependence with inhalant-induced anxiety disorder
F18.288	Inhalant dependence with other inhalant-induced disorder
F18.29	Inhalant dependence with unspecified inhalant-induced disorder
F18.9	Inhalant use, unspecified
F18.90	Inhalant use, unspecified, uncomplicated
F18.91	Inhalant use, unspecified, in remission
F18.92	Inhalant use, unspecified with intoxication
F18.920	Inhalant use, unspecified with intoxication, uncomplicated
F18.921	Inhalant use, unspecified with intoxication with delirium
F18.929	Inhalant use, unspecified with intoxication, unspecified
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder
F18.95	Inhalant use, unspecified with inhalant-induced psychotic disorder
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia
F18.98	Inhalant use, unspecified with other inhalant-induced disorders
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder
F18.988	Inhalant use, unspecified with other inhalant-induced disorder
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder
F19	Other psychoactive substance related disorders
F19.1	Other psychoactive substance abuse
F19.10	Other psychoactive substance abuse, uncomplicated
F19.11	Other psychoactive substance abuse, in remission
F19.12	Other psychoactive substance abuse with intoxication
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated
F19.121	Other psychoactive substance abuse with intoxication delirium
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances

F19.129	Other psychoactive substance abuse with intoxication, unspecified
F19.13	Other psychoactive substance abuse with withdrawal
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated
F19.131	Other psychoactive substance abuse with withdrawal delirium
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance
F19.139	Other psychoactive substance abuse with withdrawal, unspecified
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder
F19.15	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia
F19.18	Other psychoactive substance abuse with other psychoactive substance-induced disorders
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder
F19.2	Other psychoactive substance dependence
F19.20	Other psychoactive substance dependence, uncomplicated
F19.21	Other psychoactive substance dependence, in remission
F19.22	Other psychoactive substance dependence with intoxication
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated
F19.221	Other psychoactive substance dependence with intoxication delirium
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance
F19.229	Other psychoactive substance dependence with intoxication, unspecified

F19.23	Other psychoactive substance dependence with withdrawal
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated
F19.231	Other psychoactive substance dependence with withdrawal delirium
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance
F19.239	Other psychoactive substance dependence with withdrawal, unspecified
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder
F19.25	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia
F19.28	Other psychoactive substance dependence with other psychoactive substance-induced disorders
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder
F19.9	Other psychoactive substance use, unspecified
F19.90	Other psychoactive substance use, unspecified, uncomplicated
F19.91	Other psychoactive substance use, unspecified, in remission
F19.92	Other psychoactive substance use, unspecified with intoxication
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified
F19.93	Other psychoactive substance use, unspecified with withdrawal

F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder
F19.95	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia
F19.98	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorders
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder
F20	Schizophrenia
F20.0	Paranoid schizophrenia
F20.1	Disorganized schizophrenia
F20.2	Catatonic schizophrenia
F20.3	Undifferentiated schizophrenia
F20.5	Residual schizophrenia
F20.8	Other schizophrenia
F20.81	Schizophreniform disorder
F20.89	Other schizophrenia
F20.9	Schizophrenia, unspecified

F21	Schizotypal disorder
F22	Delusional disorders
F23	Brief psychotic disorder
F24	Shared psychotic disorder
F25	Schizoaffective disorders
F25.0	Schizoaffective disorder, bipolar type
F25.1	Schizoaffective disorder, depressive type
F25.8	Other schizoaffective disorders
F25.9	Schizoaffective disorder, unspecified
F28	Other psychotic disorder not due to a substance or known physiological condition
F29	Unspecified psychosis not due to a substance or known physiological condition
F30	Manic episode
F30.1	Manic episode without psychotic symptoms
F30.10	Manic episode without psychotic symptoms, unspecified
F30.11	Manic episode without psychotic symptoms, mild
F30.12	Manic episode without psychotic symptoms, moderate
F30.13	Manic episode, severe, without psychotic symptoms
F30.2	Manic episode, severe with psychotic symptoms
F30.3	Manic episode in partial remission
F30.4	Manic episode in full remission
F30.8	Other manic episodes
F30.9	Manic episode, unspecified
F31	Bipolar disorder
F31.0	Bipolar disorder, current episode hypomanic
F31.1	Bipolar disorder, current episode manic without psychotic features
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified
F31.11	Bipolar disorder, current episode manic without psychotic features, mild
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate
F31.13	Bipolar disorder, current episode manic without psychotic features, severe
F31.2	Bipolar disorder, current episode manic severe with psychotic features
F31.3	Bipolar disorder, current episode depressed, mild or moderate severity
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified
F31.31	Bipolar disorder, current episode depressed, mild
F31.32	Bipolar disorder, current episode depressed, moderate
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features

F31.6	Bipolar disorder, current episode mixed
F31.60	Bipolar disorder, current episode mixed, unspecified
F31.61	Bipolar disorder, current episode mixed, mild
F31.62	Bipolar disorder, current episode mixed, moderate
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features
F31.7	Bipolar disorder, currently in remission
F31.70	Bipolar disorder, currently in remission, most recent episode unspecified
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic
F31.72	Bipolar disorder, in full remission, most recent episode hypomanic
F31.73	Bipolar disorder, in partial remission, most recent episode manic
F31.74	Bipolar disorder, in full remission, most recent episode manic
F31.75	Bipolar disorder, in partial remission, most recent episode depressed
F31.76	Bipolar disorder, in full remission, most recent episode depressed
F31.77	Bipolar disorder, in partial remission, most recent episode mixed
F31.78	Bipolar disorder, in full remission, most recent episode mixed
F31.8	Other bipolar disorders
F31.81	Bipolar II disorder
F31.89	Other bipolar disorder
F31.9	Bipolar disorder, unspecified
F32	Depressive episode
F32.0	Major depressive disorder, single episode, mild
F32.1	Major depressive disorder, single episode, moderate
F32.2	Major depressive disorder, single episode, severe without psychotic features
F32.3	Major depressive disorder, single episode, severe with psychotic features
F32.4	Major depressive disorder, single episode, in partial remission
F32.5	Major depressive disorder, single episode, in full remission
F32.8	Other depressive episodes
F32.81	Premenstrual dysphoric disorder
F32.89	Other specified depressive episodes
F32.9	Major depressive disorder, single episode, unspecified
F32.A	Depression, unspecified
F33	Major depressive disorder, recurrent
F33.0	Major depressive disorder, recurrent, mild
F33.1	Major depressive disorder, recurrent, moderate
F33.2	Major depressive disorder, recurrent, severe without psychotic features
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms

F33.4	Major depressive disorder, recurrent, in remission
F33.40	Major depressive disorder, recurrent, in remission, unspecified
F33.41	Major depressive disorder, recurrent, in partial remission
F33.42	Major depressive disorder, recurrent, in full remission
F33.8	Other recurrent depressive disorders
F33.9	Major depressive disorder, recurrent, unspecified
F34	Persistent mood [affective] disorders
F34.0	Cyclothymic disorder
F34.1	Dysthymic disorder
F34.8	Other persistent mood [affective] disorders
F34.81	Disruptive mood dysregulation disorder
F34.89	Other specified persistent mood disorders
F34.9	Persistent mood [affective] disorder, unspecified
F39	Unspecified mood [affective] disorder
F40	Phobic anxiety disorders
F40.0	Agoraphobia
F40.00	Agoraphobia, unspecified
F40.01	Agoraphobia with panic disorder
F40.02	Agoraphobia without panic disorder
F40.1	Social phobias
F40.10	Social phobia, unspecified
F40.11	Social phobia, generalized
F40.2	Specific (isolated) phobias
F40.21	Animal type phobia
F40.210	Arachnophobia
F40.218	Other animal type phobia
F40.22	Natural environment type phobia
F40.220	Fear of thunderstorms
F40.228	Other natural environment type phobia
F40.23	Blood, injection, injury type phobia
F40.230	Fear of blood
F40.231	Fear of injections and transfusions
F40.232	Fear of other medical care
F40.233	Fear of injury
F40.24	Situational type phobia
F40.240	Claustrophobia
F40.241	Acrophobia

F40.242	Fear of bridges
F40.243	Fear of flying
F40.248	Other situational type phobia
F40.29	Other specified phobia
F40.290	Androphobia
F40.291	Gynephobia
F40.298	Other specified phobia
F40.8	Other phobic anxiety disorders
F40.9	Phobic anxiety disorder, unspecified
F41	Other anxiety disorders
F41.0	Panic disorder [episodic paroxysmal anxiety]
F41.1	Generalized anxiety disorder
F41.3	Other mixed anxiety disorders
F41.8	Other specified anxiety disorders
F41.9	Anxiety disorder, unspecified
F42	Obsessive-compulsive disorder
F42.2	Mixed obsessional thoughts and acts
F42.3	Hoarding disorder
F42.4	Excoriation (skin-picking) disorder
F42.8	Other obsessive-compulsive disorder
F42.9	Obsessive-compulsive disorder, unspecified
F43	Reaction to severe stress, and adjustment disorders
F43.0	Acute stress reaction
F43.1	Post-traumatic stress disorder (PTSD)
F43.10	Post-traumatic stress disorder, unspecified
F43.11	Post-traumatic stress disorder, acute
F43.12	Post-traumatic stress disorder, chronic
F43.2	Adjustment disorders
F43.20	Adjustment disorder, unspecified
F43.21	Adjustment disorder with depressed mood
F43.22	Adjustment disorder with anxiety
F43.23	Adjustment disorder with mixed anxiety and depressed mood
F43.24	Adjustment disorder with disturbance of conduct
F43.25	Adjustment disorder with mixed disturbance of emotions and conduct
F43.29	Adjustment disorder with other symptoms
F43.8	Other reactions to severe stress
F43.81	Prolonged grief disorder

F43.89	Other reactions to severe stress
F43.9	Reaction to severe stress, unspecified
F44	Dissociative and conversion disorders
F44.0	Dissociative amnesia
F44.1	Dissociative fugue
F44.2	Dissociative stupor
F44.4	Conversion disorder with motor symptom or deficit
F44.5	Conversion disorder with seizures or convulsions
F44.6	Conversion disorder with sensory symptom or deficit
F44.7	Conversion disorder with mixed symptom presentation
F44.8	Other dissociative and conversion disorders
F44.81	Dissociative identity disorder
F44.89	Other dissociative and conversion disorders
F44.9	Dissociative and conversion disorder, unspecified
F45	Somatoform disorders
F45.0	Somatization disorder
F45.1	Undifferentiated somatoform disorder
F45.2	Hypochondriacal disorders
F45.20	Hypochondriacal disorder, unspecified
F45.21	Hypochondriasis
F45.22	Body dysmorphic disorder
F45.29	Other hypochondriacal disorders
F45.4	Pain disorders related to psychological factors
F45.41	Pain disorder exclusively related to psychological factors
F45.42	Pain disorder with related psychological factors
F45.8	Other somatoform disorders
F45.9	Somatoform disorder, unspecified
F48	Other nonpsychotic mental disorders
F48.1	Depersonalization-derealization syndrome
F48.2	Pseudobulbar affect
F48.8	Other specified nonpsychotic mental disorders
F48.9	Nonpsychotic mental disorder, unspecified
F50	Eating disorders
F50.0	Anorexia nervosa
F50.00	Anorexia nervosa, unspecified
F50.01	Anorexia nervosa, restricting type
F50.010	Anorexia nervosa, restricting type, mild

F50.011	Anorexia nervosa, restricting type, moderate
F50.012	Anorexia nervosa, restricting type, severe
F50.013	Anorexia nervosa, restricting type, extreme
F50.014	Anorexia nervosa, restricting type, in remission
F50.019	Anorexia nervosa, restricting type, unspecified
F50.02	Anorexia nervosa, binge eating/purging type
F50.020	Anorexia nervosa, binge eating/purging type, mild
F50.021	Anorexia nervosa, binge eating/purging type, moderate
F50.022	Anorexia nervosa, binge eating/purging type, severe
F50.023	Anorexia nervosa, binge eating/purging type, extreme
F50.024	Anorexia nervosa, binge eating/purging type, in remission
F50.029	Anorexia nervosa, binge eating/purging type, unspecified
F50.2	Bulimia nervosa
F50.20	Bulimia nervosa, unspecified
F50.21	Bulimia nervosa, mild
F50.22	Bulimia nervosa, moderate
F50.23	Bulimia nervosa, severe
F50.24	Bulimia nervosa, extreme
F50.25	Bulimia nervosa, in remission
F50.8	Other eating disorders
F50.81	Binge eating disorder
F50.810	Binge eating disorder, mild
F50.811	Binge eating disorder, moderate
F50.812	Binge eating disorder, severe
F50.813	Binge eating disorder, extreme
F50.814	Binge eating disorder, in remission
F50.819	Binge eating disorder, unspecified
F50.82	Avoidant/restrictive food intake disorder
F50.83	Pica in adults
F50.84	Rumination disorder in adults
F50.89	Other specified eating disorder
F50.9	Eating disorder, unspecified
F51	Sleep disorders not due to a substance or known physiological condition
F51.0	Insomnia not due to a substance or known physiological condition
F51.01	Primary insomnia
F51.02	Adjustment insomnia
F51.03	Paradoxical insomnia

F51.04	Psychophysiological insomnia
F51.05	Insomnia due to other mental disorder
F51.09	Other insomnia not due to a substance or known physiological condition
F51.1	Hypersomnia not due to a substance or known physiological condition
F51.11	Primary hypersomnia
F51.12	Insufficient sleep syndrome
F51.13	Hypersomnia due to other mental disorder
F51.19	Other hypersomnia not due to a substance or known physiological condition
F51.3	Sleepwalking [somnambulism]
F51.4	Sleep terrors [night terrors]
F51.5	Nightmare disorder
F51.8	Other sleep disorders not due to a substance or known physiological condition
F51.9	Sleep disorder not due to a substance or known physiological condition, unspecified
F52	Sexual dysfunction not due to a substance or known physiological condition
F52.0	Hypoactive sexual desire disorder
F52.1	Sexual aversion disorder
F52.2	Sexual arousal disorders
F52.21	Male erectile disorder
F52.22	Female sexual arousal disorder
F52.3	Orgasmic disorder
F52.31	Female orgasmic disorder
F52.32	Male orgasmic disorder
F52.4	Premature ejaculation
F52.5	Vaginismus not due to a substance or known physiological condition
F52.6	Dyspareunia not due to a substance or known physiological condition
F52.8	Other sexual dysfunction not due to a substance or known physiological condition
F52.9	Unspecified sexual dysfunction not due to a substance or known physiological condition
F53	Mental and behavioral disorders associated with the puerperium, not elsewhere classified
F53.0	Postpartum depression
F53.1	Puerperal psychosis
F54	Psychological and behavioral factors associated with disorders or diseases classified elsewhere
F55	Abuse of non-psychoactive substances
F55.0	Abuse of antacids
F55.1	Abuse of herbal or folk remedies

F55.2	Abuse of laxatives
F55.3	Abuse of steroids or hormones
F55.4	Abuse of vitamins
F55.8	Abuse of other non-psychoactive substances
F59	Unspecified behavioral syndromes associated with physiological disturbances and physical factors
F60	Specific personality disorders
F60.0	Paranoid personality disorder
F60.1	Schizoid personality disorder
F60.2	Antisocial personality disorder
F60.3	Borderline personality disorder
F60.4	Histrionic personality disorder
F60.5	Obsessive-compulsive personality disorder
F60.6	Avoidant personality disorder
F60.7	Dependent personality disorder
F60.8	Other specific personality disorders
F60.81	Narcissistic personality disorder
F60.89	Other specific personality disorders
F60.9	Personality disorder, unspecified
F63	Impulse disorders
F63.0	Pathological gambling
F63.1	Pyromania
F63.2	Kleptomania
F63.3	Trichotillomania
F63.8	Other impulse disorders
F63.81	Intermittent explosive disorder
F63.89	Other impulse disorders
F63.9	Impulse disorder, unspecified
F64	Gender identity disorders
F64.0	Transsexualism
F64.1	Dual role transvestism
F64.2	Gender identity disorder of childhood
F64.8	Other gender identity disorders
F64.9	Gender identity disorder, unspecified
F65	Paraphilic disorders
F65.0	Fetishism
F65.1	Transvestic fetishism

F65.2	Exhibitionism
F65.3	Voyeurism
F65.4	Pedophilia
F65.5	Sadomasochism
F65.50	Sadomasochism, unspecified
F65.51	Sexual masochism
F65.52	Sexual sadism
F65.8	Other paraphilic disorders
F65.81	Frotteurism
F65.89	Other paraphilic disorders
F65.9	Paraphilia, unspecified
F66	Other sexual disorders
F68	Other disorders of adult personality and behavior
F68.1	Factitious disorder imposed on self
F68.10	Factitious disorder imposed on self, unspecified
F68.11	Factitious disorder imposed on self, with predominantly psychological signs and symptoms
F68.12	Factitious disorder imposed on self, with predominantly physical signs and symptoms
F68.13	Factitious disorder imposed on self, with combined psychological and physical signs and symptoms
F68.A	Factitious disorder imposed on another
F68.8	Other specified disorders of adult personality and behavior
F69	Unspecified disorder of adult personality and behavior
F70	Mild intellectual disabilities
F71	Moderate intellectual disabilities
F72	Severe intellectual disabilities
F73	Profound intellectual disabilities
F78	Other intellectual disabilities
F78.A	Other genetic related intellectual disabilities
F78.A1	SYNGAP1-related intellectual disability
F78.A9	Other genetic related intellectual disability
F79	Unspecified intellectual disabilities
F80	Specific developmental disorders of speech and language
F80.0	Phonological disorder
F80.1	Expressive language disorder
F80.2	Mixed receptive-expressive language disorder
F80.4	Speech and language development delay due to hearing loss

F80.8	Other developmental disorders of speech and language
F80.81	Childhood onset fluency disorder
F80.82	Social pragmatic communication disorder
F80.89	Other developmental disorders of speech and language
F80.9	Developmental disorder of speech and language, unspecified
F81	Specific developmental disorders of scholastic skills
F81.0	Specific reading disorder
F81.2	Mathematics disorder
F81.8	Other developmental disorders of scholastic skills
F81.81	Disorder of written expression
F81.89	Other developmental disorders of scholastic skills
F81.9	Developmental disorder of scholastic skills, unspecified
F82	Specific developmental disorder of motor function
F84	Pervasive developmental disorders
F84.0	Autistic disorder
F84.3	Other childhood disintegrative disorder
F84.5	Asperger's syndrome
F84.8	Other pervasive developmental disorders
F84.9	Pervasive developmental disorder, unspecified
F88	Other disorders of psychological development
F89	Unspecified disorder of psychological development
F90	Attention-deficit hyperactivity disorders
F90.0	Attention-deficit hyperactivity disorder, predominantly inattentive type
F90.2	Attention-deficit hyperactivity disorder, combined type
F90.9	Attention-deficit hyperactivity disorder, unspecified type
F91.0	Conduct disorder confined to family context
F91.1	Conduct disorder, childhood-onset type
F91.2	Conduct disorder, adolescent-onset type
F93.9	Childhood emotional disorder, unspecified
F94	Disorders of social functioning with onset specific to childhood and adolescence
F94.8	Other childhood disorders of social functioning
F94.9	Childhood disorder of social functioning, unspecified
F95.2	Tourette's disorder
F95.8	Other tic disorders
F95.9	Tic disorder, unspecified
F98	Other behavioral and emotional disorders with onset usually occurring in childhood and adolescence

F98.0	Enuresis not due to a substance or known physiological condition
F98.2	Other feeding disorders of infancy and childhood
F98.21	Rumination disorder of infancy and childhood
F98.29	Other feeding disorders of infancy and early childhood
F98.3	Pica of infancy and childhood
F98.4	Stereotyped movement disorders
F98.5	Adult onset fluency disorder
F98.8	Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence
F98.9	Unspecified behavioral and emotional disorders with onset usually occurring in childhood and adolescence
F99	Mental disorder, not otherwise specified
I69.091	Dysphagia following nontraumatic subarachnoid hemorrhage
I69.191	Dysphagia following nontraumatic intracerebral hemorrhage
I69.291	Dysphagia following other nontraumatic intracranial hemorrhage
I69.391	Dysphagia following cerebral infarction
I69.891	Dysphagia following other cerebrovascular disease
I69.991	Dysphagia following unspecified cerebrovascular disease
K22.4	Dyskinesia of esophagus
K50.00	Crohn's disease of small intestine without complications
K50.01	Crohn's disease of small intestine with complications
K50.011	Crohn's disease of small intestine with rectal bleeding
K50.012	Crohn's disease of small intestine with intestinal obstruction
K50.013	Crohn's disease of small intestine with fistula
K50.014	Crohn's disease of small intestine with abscess
K50.018	Crohn's disease of small intestine with other complication
K50.019	Crohn's disease of small intestine with unspecified complications
K50.1	Crohn's disease of large intestine
K50.10	Crohn's disease of large intestine without complications
K50.11	Crohn's disease of large intestine with complications
K50.111	Crohn's disease of large intestine with rectal bleeding
K50.112	Crohn's disease of large intestine with intestinal obstruction
K50.113	Crohn's disease of large intestine with fistula
K50.114	Crohn's disease of large intestine with abscess

K50.118	Crohn's disease of large intestine with other complication
K50.119	Crohn's disease of large intestine with unspecified complications
K50.8	Crohn's disease of both small and large intestine
K50.80	Crohn's disease of both small and large intestine without complications
K50.81	Crohn's disease of both small and large intestine with complications
K50.811	Crohn's disease of both small and large intestine with rectal bleeding
K50.812	Crohn's disease of both small and large intestine with intestinal obstruction
K50.813	Crohn's disease of both small and large intestine with fistula
K50.814	Crohn's disease of both small and large intestine with abscess
K50.818	Crohn's disease of both small and large intestine with other complication
K50.819	Crohn's disease of both small and large intestine with unspecified complications
K50.9	Crohn's disease, unspecified
K50.90	Crohn's disease, unspecified, without complications
K50.91	Crohn's disease, unspecified, with complications
K50.911	Crohn's disease, unspecified, with rectal bleeding
K50.912	Crohn's disease, unspecified, with intestinal obstruction
K50.913	Crohn's disease, unspecified, with fistula
K50.914	Crohn's disease, unspecified, with abscess
K50.918	Crohn's disease, unspecified, with other complication
K50.919	Crohn's disease, unspecified, with unspecified complications
N17.0	Acute kidney failure with tubular necrosis
N17.1	Acute kidney failure with acute cortical necrosis
N17.2	Acute kidney failure with medullary necrosis
N17.8	Other acute kidney failure
N17.9	Acute kidney failure, unspecified
O21.0	Mild hyperemesis gravidarum
O21.1	Hyperemesis gravidarum with metabolic disturbance
O21.2	Late vomiting of pregnancy
O21.8	Other vomiting complicating pregnancy
O21.9	Vomiting of pregnancy, unspecified
R13.0	Aphagia
R13.1	Dysphagia
R13.10	Dysphagia, unspecified
R13.11	Dysphagia, oral phase

R13.12	Dysphagia, oropharyngeal phase
R13.13	Dysphagia, pharyngeal phase
R13.14	Dysphagia, pharyngoesophageal phase
R13.19	Other dysphagia
Z93.1	Gastrostomy status
Z93.4	Other artificial openings of gastrointestinal tract status
Z99.2	Dependence on renal dialysis

Table 3	
CPT/HCPCS codes for medical foods considered experimental, investigational or unproven.	
Code	Description
A9152	Single vitamin/mineral/trace element, oral, per dose, not otherwise specified
A9153	Multiple vitamins, with or without minerals and trace elements, oral, per dose, not otherwise specified
B4100	Food thickener, administered orally, per oz
B4102	Enteral formula, for adults, used to replace fluids and electrolytes (e.g., clear liquids), 500 ml = 1 unit
B4103	Enteral formula, for pediatrics, used to replace fluids and electrolytes (e.g., clear liquids), 500 ml = 1 unit
B4104	Additive for enteral formula (e.g., fiber)
B4105	Relizorb (digestive enzyme cartridge) In-line cartridge containing digestive enzyme(s) for enteral feeding, each

References

1. Academy of Nutrition and Dietetics. Evidence-based nutrition practice guidelines. <http://www.eatrightpro.org/practice/guidelines-and-positions/evidence-based-nutrition-practice-guidelines> (Accessed on March 13, 2023)
2. Alresta Therapeutics Inc. Relizorb (immobilized lipase) cartridge [healthcare provider version]. Available at: <https://www.relizorb.com/hcp>.
3. Alresta Therapeutics Inc. Relizorb (immobilized lipase) cartridge [instructions for use; PDF]. 06/2024. Available at: <https://www.relizorb.com/docs/pdfs/Relizorb-Instructions-for-Use.pdf>.
4. American Academy of Pediatrics Committee on Nutrition. Reimbursement for medical foods for inborn errors of metabolism. Pediatrics. 1994;93(5):860.

5. American Society for Parenteral and Enteral Nutrition (ASPEN). Clinical guidelines: the validity of body composition assessment in clinical populations. 2020; 44(1):12-43.
6. ASPEN | Enteral Nutrition Formula Guide. (n.d.).
https://www.nutritioncare.org/Guidelines_and_Clinical_Resources/EN_Formula_Guide/Enteral_Nutrition_Formula_Guide/
7. Ayoob KT, Barresi I. Feeding disorders in children: taking an interdisciplinary approach. *Pediatr Ann.* 2007; 36(8):478-483.
8. Baker R (2023). Cystic fibrosis: Nutritional issues. UpToDate. Available from <https://www.uptodate.com/contents/overview-of-enteral-parenteral-nutrition>. (Accessed March 11, 2023)
9. Baker ML, Halliday V, Robinson P, et al. Nutrient intake and contribution of home enteral nutrition to meeting nutritional requirements after oesophagectomy and total gastrectomy. *Eur J Clin Nutr.* 2017; 71(9):1121-1128.
10. Baldwin, C., Parsons, T., Logam, S. Dietary Advice and Oral Supplements for Illness-Related Malnutrition in Adults. The Cochrane Database of Systemic Reviews. The Cochrane Library 2000.
11. Bankhead R, Boullata J, Brantley S, Corkins M, Guenter P, Krenitsky J, Lyman B, Metheny recommendations. *JPEN J Parenter Enteral Nutr.* 2009 Mar-Apr;33(2):122-67.
12. Berry AJ. Pancreatic surgery: indications, complications, and implications for nutrition intervention. *Nutr Clin Pract.* 2013 Jun;28(3):330-57.
13. Boullata JI, et al. A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing. *Journal of Parenteral and Enteral Nutrition* 2014 Mar-Apr;38(3):334-377. DOI: 10.1177/0148607114521833. (Reaffirmed 2021 Aug)
14. Cagler D (2017). Evaluation of weight loss in infants over six months of age, children, and adolescents. UpToDate. Available from <https://www.uptodate.com/contents/evaluation-of-weight-loss-in-infants-over-six-months-of-age-children-and-adolescents>. (Accessed February 10, 2017)
15. California Code of Regulations [CCR], Title 22, Section 51313.3. Available at: <https://files.medi-cal.ca.gov/pubsdocs/Publications/masters-MTP/Part2/enteral.pdf>. Accessed March 7, 2023.
16. Careaga, M.G., Kerner, J.A. A Gastroenterologist's Approach to Failure to Thrive. *Pediatric Annals* 2000; 29 (9): 558-567.
17. CDC Growth Charts. Available at: http://www.cdc.gov/growthcharts/cdc_charts.htm. (Accessed on March 13, 2023)
18. Center for Devices and Radiological Health (CDRH). K191379. RELiZORB [PDF]. December 4, 2019. Food and Drug Administration [website]. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf19/K191379.pdf.
19. Chen X, Zhao G, Zhu L. Home enteral nutrition for postoperative elderly patients with esophageal cancer. *Ann Palliat Med.* 2021; 10(1):278-284.
20. Collier S (2017). Overview of enteral nutrition in infants and children. UpToDate. Available from <https://www.uptodate.com/contents/overview-of-enteral-nutrition-in-infants-and-children>. (Accessed February 9, 2017)

21. Compher C, Bingham AL, McCall M, Patel J, Rice TW, Braunschweig C, McKeever L. Guidelines for the provision of nutrition support therapy in the adult critically ill patient: The American Society for Parenteral and Enteral Nutrition. *JPEN J Parenter Enteral Nutr.* 2021 Nov 16.
22. Cooper-Brown L, Copeland S, Dailey S, et al. Feeding and swallowing dysfunction in genetic syndromes. *Dev Disabil Res Rev.* 2008; 14(2):147-157.
23. Corbett SS, Drewett RF. To what extent is failure to thrive in infancy associated with poorer cognitive development? A review and meta-analysis. *J Child Psychol Psychiatry* 2004; 45:641.
24. Crosby J, Duerksen DR. A prospective study of tube- and feeding-related complications in patients receiving long-term home enteral nutrition. *JPEN J Parenter Enteral Nutr.* 2007; 31(4):274-277.
25. DeLegge MH, et al. Nutrition and dietary management for adults with inflammatory bowel disease. *UpToDate.* (Accessed March 11, 2023)
26. Dipasquale V, Ventimiglia M, Gramaglia SMC, et al. Health-related quality of life and home enteral nutrition in children with neurological impairment: report from a multicenter survey. *Nutrients.* 2019; 11(12):2968.
27. Donohoe CL, Healy LA, Fanning M, et al. Impact of supplemental home enteral feeding postesophagectomy on nutrition, body composition, quality of life, and patient satisfaction. *Dis Esophagus.* 2017; 30(9):1-9.
28. Duryea TK (2017). Poor weight gain in children older than two years of age. *UpToDate.* Available from <https://www.uptodate.com/contents/poor-weight-gain-in-children-older-than-two-years-of-age>. (Accessed February 10, 2017)
29. Embleton ND, Jennifer Moltu S, Lapillonne A, van den Akker CHP, Carnielli V, Fusch C, Gerasimidis K, van Goudoever JB, Haiden N, Iacobelli S, Johnson MJ, Meyer S, Mihatsch W, de Pipaon MS, Rigo J, Zachariassen G, Bronsky J, Indrio F, Köglmeier J, de Koning B, Norsa L, Verduci E, Domellöf M. Enteral Nutrition in Preterm Infants (2022): A Position Paper From the ESPGHAN Committee on Nutrition and Invited Experts. *J Pediatr Gastroenterol Nutr.* 2023 Feb 1;76(2):248-268. doi: 10.1097/MPG.0000000000003642. Epub 2022 Oct 28. PMID: 36705703.
30. Fleet S (2022). Overview of enteral nutrition in infants and children. *UpToDate.* Available from <https://www.uptodate.com/contents/overview-of-enteral-parenteral-nutrition>. (Accessed March 11, 2023)
31. Fortunato JE, Scheimann AO. Protein-energy malnutrition and feeding refusal secondary to food allergies. *Clin Pediatr (Phila)* 2008; 47:496.
32. Freedman S, Orenstein D, Black P, et al. Increased fat absorption from enteral formula through an in-line digestive cartridge in patients with cystic fibrosis. *J Pediatr Gastroenterol Nutr.* 2017;65(1):97-101.
33. Gaddey HL, Holder K. Unintentional Weight Loss in Older Adults. *Am Fam Physician.* 2014 May 1;89(9):718-722.
34. Gastroenterology & Hepatology. 2012;8(6):393-395.

35. Gavazzi C, Colatruglio S, Valoriani F, et al. Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: a multicentre randomised clinical trial. *Eur J Cancer*. 2016; 64:107-112.
36. Grooten IJ, Koot MH, van der Post JA, et al. Early enteral tube feeding in optimizing treatment of hyperemesis gravidarum: the Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding (MOTHER) randomized controlled trial. *Am J Clin Nutr*. 2017; 106(3):812-820.
37. Hair A (2022). Approach to enteral nutrition in the premature infant. UpToDate. Available from <https://www.uptodate.com/contents/overview-of-enteral-parenteral-nutrition>. (Accessed March 11, 2023)
38. H.R.3665 - Medical Foods Equity Act of 2013. 113th Congress (2013-2014) <<https://www.congress.gov/bill/113th-congress/house-bill/3665>> (Accessed February 6, 2017)
39. Haddad RY, Thomas DR. Enteral nutrition and enteral tube feeding. Review of the evidence. *Clin Geriatr Med*. 2002; 18(4):867-881.
40. Heyland DK. Enteral and parenteral nutrition in the seriously ill, hospitalized patient: A critical review of the evidence. *J Nutr Health Aging*. 2000;4(1):31-41.
41. Homan GJ. Failure to Thrive: A Practical Guide. *Am Fam Physician*. 2016 Aug 15;94(4):295-299.
42. Høst A, Koletzko B, Dreborg S, et al. Dietary products used in infants for treatment & prevention of food allergy. Joint Statement of the European Society for Paediatric Allergology and Clinical Immunology (ESPACI) Committee on Hypoallergenic Formulas and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition. *Arch Dis Child*. 1999; 81(1):80-84.
43. Hughes I. Confusing terminology attempts to define the undefinable. *Arch Dis Child* 2007; 92:97
44. Jatoi A (2022). The role of parenteral and enteral/oral nutritional support in patients with cancer. UpToDate. Available from <https://www.uptodate.com/contents/overview-of-enteral-parenteral-nutrition>. (Accessed March 11, 2023)
45. Joly F, Dray X, Corcos O, et al. Tube feeding improves intestinal absorption in short bowel syndrome patients. *Gastroenterology*. 2009; 136(3):824-831.
46. Kane ML. Pediatric failure to thrive. *Clin Fam Pract*. 2003; 5(2):293-311.
47. Kirkland RT (2017). Failure to thrive (undernutrition) in children younger than two years: Etiology and evaluation. UpToDate. Available from <https://www.uptodate.com/contents/failure-to-thrive-undernutrition-in-children-younger-than-two-years-etiology-and-evaluation>. (Accessed February 10, 2017)
48. Kirkland RT (2017). Failure to thrive (undernutrition) in children younger than two years: management. UpToDate. Available from <https://www.uptodate.com/contents/failure-to-thrive-undernutrition-in-children-younger-than-two-years-management>. (Accessed February 10, 2017)
49. Klek S, Hermanowicz A, Dziwiszek G, et al. Home enteral nutrition reduces complications, length of stay, and health care costs: results from a multicenter study. *Am J Clin Nutr*. 2014; 100(2):609-615.

50. Kodak T, Piazza CC. Assessment and behavioral treatment of feeding and sleeping disorders in children with autism spectrum disorders. *Child Adolesc Psychiatr Clin N Am.* 2008; 17(4):887-905.
51. Krugman SD, Dubowitz H. Failure to thrive. *Am Fam Physician.* 2003; 68(5):879-884.
52. Li XK, Cong ZZ, Wu WJ, et al. Efficacy of 4 wk of home enteral feeding supplementation after esophagectomy on immune function: A randomized controlled trial. *Nutrition.* 2020; 77:110787.
53. Lifschitz CH. Feeding problems in infants and children. *Curr Treat Options Gastroenterol.* 2001; 4(5):451-457.
54. MacFie J. Enteral versus parenteral nutrition. *Br J Surg.* 2000;87(9):1121-1122.
55. Maldonado J, Gil A, Narbona E, Molina JA. Special formulas in infant nutrition: A review. *Early Hum Dev.* 1998;53 Suppl:S23-S32.
56. Manikin R, Perman JA. Pediatric feeding disorders. *J Clin Gastroenterol.* 2002; 30(1):34-46.
57. Mass. Gen. Laws Ch. 176B Section 4K, Coverage for nonprescription enteral formulas for home use. Available at:
<https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXXII/Chapter176B/Section4K>. Accessed March 7, 2023.
58. McClave SA, DiBaise JK, Mullin GE, Martindale RG. ACG Clinical Guideline: Nutrition Therapy in the Adult Hospitalized Patient. *Am J Gastroenterol.* 2016 Mar;111(3):315-34.
59. McClave SA, Taylor BE, Martindale RG, et. Al., Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient; Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). *JPEN J Parenter Enteral Nutr* 2016;40:159-211.
60. Medscape, LLC. FDA clears Relizorb for use with enteral tube feedings. Medscape, LLC. New York, NY. December 03, 2015.
61. Mehta NM, Skillman HE, Irving SY, Coss-Bu JA, Vermilyea S, Farrington EA, McKeever L, Hall AM, Goday PS, Braunschweig C. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition. *JPEN J Parenter Enteral Nutr.* 2017 Jul;41(5):706-742.
62. Mitchell LJ, Ball LE, Ross LJ, etc. Effectiveness of Dietetic Consultations in Primary Health Care: A Systematic Review of Randomized Controlled Trials. *J Acad Nutr Diet.* 2017; 117(12):1941-1962.
63. Mofidi S. Nutritional management of pediatric food hypersensitivity. *Pediatrics* 2003; 111:1645.
64. Moore JV, Scoggins CR, Philips P, Egger ME, Martin RCG 2nd. Optimization of Exocrine Pancreatic Insufficiency in Pancreatic Adenocarcinoma Patients. *Nutrients.* 2024 Oct 15;16(20):3499. doi: 10.3390/nu16203499. PMID: 39458494; PMCID: PMC11510683.
65. Mueller C, Compher C, Ellen DM, et al. A.S.P.E.N. clinical guidelines: Nutrition screening, assessment, and intervention in adults. *JPEN J Parenter Enteral Nutr.* 2011 Jan;35(1):16-24.
66. NA, Mueller C, Robbins S, Wessel J; A.S.P.E.N. Board of Directors. Enteral nutrition practice

67. Nakajoh K, Nakagawa T, Sekizawa K, et al. Relation between incidence of pneumonia and protective reflexes in post-stroke patients with oral or tube feeding. *J Intern Med.* 2000; 247(1):39-42.
68. National Institutes of Health. National Library of Medicine. Medical Encyclopedia. Inborn errors of metabolism. May 2021. Available at URL address: <http://www.nlm.nih.gov/medlineplus/ency/article/002438.htm>
69. New Jersey Permanent Statutes Title 17B. http://lis.njleg.state.nj.us/cgi-bin/om_isapi.dll?clientID=1343166106&Depth=2&depth=2&expandheadings=on&headingswithhits=on&hitsperheading=on&infobase=statutes.nfo&record={72B3}&softpage=Doc_Frame_PG42. (Accessed March 14, 2017)
70. New York Insurance Law § 4303(y). <http://codes.findlaw.com/ny/insurance-law/isc-sect-4303.html#sthash.5vX0Vzat.dpuf>. (Accessed March 14, 2017)
71. Ojo O, Brooke J. The Use of Enteral Nutrition in the Management of Stroke. *Nutrients.* 2016;8(12):827.
72. Olsen EM, Petersen J, Skovgaard AM, et al. Failure to thrive: the prevalence and concurrence of anthropometric criteria in a general infant population. *Arch Dis Child* 2007; 92:109.
73. Perrin E, Frank D, Cole C, et al. Criteria for Determining Disability in Infants and Children: Failure to Thrive. Evidence Report/Technology Assessment No. 72. AHRQ Publication NO. 03-E026. Agency for Healthcare Research and Quality, Rockville, MD, March 2003.
74. Peterson KE, Chen LC. Defining undernutrition for public health purposes in the United States. *J Nutr* 1990; 120:933.
75. RI Gen L § 27-41-74 (2021) Enteral nutrition products. Available at: <https://law.justia.com/codes/rhode-island/2021/title-27/chapter-27-41/section-27-41-74/>. Accessed March 7, 2023.
76. Riley LK, et al. Nutrition in Toddlers. *Am Fam Physician.* 2018 Aug 15;98(4):227-233.
77. Riva E, Fiocchi A, Fiori L, Giovannini M. Prevention and treatment of cow's milk allergy. *Arch Dis Child.* 2001; 84(1):91.
78. Romanowski K (2021). Overview of nutrition support in burn patients. UpToDate. Available from <https://www.uptodate.com/contents/overview-of-enteral-parenteral-nutrition>. (Accessed March 11, 2023)
79. Romanowski K (2021). Overview of perioperative nutrition support. UpToDate. Available from <https://www.uptodate.com/contents/overview-of-enteral-parenteral-nutrition>. (Accessed March 11, 2023)
80. Sathe, M.N., Patel, D., Stone, A. and First, E. (2021), Evaluation of the Effectiveness of In-line Immobilized Lipase Cartridge in Enterally Fed Patients With Cystic Fibrosis. *Journal of Pediatric Gastroenterology and Nutrition*, 72: 18-23. <https://doi.org/10.1097/MPG.0000000000002984>
81. Schanier RJ (2017). Approach to enteral nutrition in the premature infant. UpToDate. Available from <https://www.uptodate.com/contents/approach-to-enteral-nutrition-in-the-premature-infant>. (Accessed February 9, 2017)

82. Schwarzenberg SJ, Hempstead SE, McDonald CM, Powers SW, Wooldridge J, Blair S, Freedman S, Harrington E, Murphy PJ, Palmer L, Schrader AE, Shiel K, Sullivan J, Wallentine M, Marshall BC, Leonard AR. Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines. *J Cyst Fibros.* 2016 Nov;15(6):724-735. doi: 10.1016/j.jcf.2016.08.004. Epub 2016 Sep 3. PMID: 27599607.

83. Schwenk WF 2nd. Specialized nutrition support: the pediatric perspective. *JPEN J Parenter Enteral Nutr.* 2003; 27(3):160-167.

84. Semrad CE. Use of Parenteral Nutrition in Patients with Inflammatory Bowel Disease.

85. Seres D (2023). Nutrition support in critically ill patients: An overview. UpToDate. Available from <https://www.uptodate.com/contents/overview-of-enteral-parenteral-nutrition>. (Accessed March 11, 2023)

86. Sheean P, Gonzalez MC, Prado CM, McKeever L, Hall AM, Braunschweig CA. American Society for Parenteral and Enteral Nutrition Clinical Guidelines: The Validity of Body Composition Assessment in Clinical Populations. *JPEN J Parenter Enteral Nutr.* 2020 Jan;44(1):12-43. doi: 10.1002/jpen.1669. Epub 2019 Jun 19.

87. Siparsky N (2022). Postoperative parenteral nutrition in adults. UpToDate. Available from <https://www.uptodate.com/contents/overview-of-enteral-parenteral-nutrition>. (Accessed March 11, 2023)

88. Smith AE, Shah M, Badireddy M. Failure to Thrive. 2023 Nov 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan--.

89. Smith JA (2017). Treatment and outcome of nausea and vomiting of pregnancy. UpToDate. Available from: <https://www.uptodate.com/contents/treatment-and-outcome-of-nausea-and-vomiting-of-pregnancy>. (Accessed February 9, 2017)

90. Sonkusare S. The clinical management of hyperemesis gravidarum. *Arch Gynecol Obstet.* 2011; 283(6):1183-1192.

91. Spencer NJ. Failure to think about failure to thrive. *Arch Dis Child* 2007; 92:95.

92. Steinglass J (2021). Anorexia nervosa in adults and adolescents: Nutritional rehabilitation (nutritional support). UpToDate. Available from <https://www.uptodate.com/contents/overview-of-enteral-parenteral-nutrition>. (Accessed March 11, 2023)

93. Stevens J, Wyatt C, Brown P, Patel D, Grujic D, Freedman SD. Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study in Patients With Cystic Fibrosis Receiving Enteral Feeding. *J Pediatr Gastroenterol Nutr.* 2018 Oct;67(4):527-532. doi: 10.1097/MPG.0000000000002110. PMID: 30074573; PMCID: PMC6155360.

94. Stratton, R. Summary of a Systemic Review on Oral Nutritional Supplements Use in the Community. *Proceedings of the Nutrition Society* 2000; 59:Aug. 467-469

95. Texas Insurance Code Chapter 1377. Coverage for Certain Amino Acid-Based Elemental Formulas. <http://www.statutes.legis.state.tx.us/Docs/IN/htm/IN.1377.htm>. (Accessed March 14, 2017)

96. Tsikis ST, Fligor SC, Mitchell PD, Hirsch TI, Carbeau S, First E, Loring G, Rudie C, Freedman SD, Martin CR, Gura KM, Puder M. Fat digestion using RELiZORB in children with short bowel syndrome who are dependent on parenteral nutrition: Protocol for a 90-day, phase 3, open labeled study. *PLoS One*. 2023 Mar 1;18(3):e0282248. doi: 10.1371/journal.pone.0282248. PMID: 36857339; PMCID: PMC9977023.
97. U.S. Food and Drug Administration (FDA). Center for Food Safety and Applied Nutrition. Office of Nutritional Products, Labeling, and Dietary Supplements. May 2016: Frequently Asked Questions about Medical Foods. . Available at: <https://www.fda.gov/media/97726/download>.
98. U.S. Food and Drug Administration (FDA). Regulatory Information. Section 5 of Orphan Drug Act. Available at:
<http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/MedicalFoods/default.htm>.
99. U.S. Food and Drug Administration. 510(k) Summary. K161247. Relizorb™. 2016 June 30. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K161247>
100. U.S. Food and Drug Administration. 510(k) Summary. K163057. Relizorb™. 2017 July 12. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K163057>
101. U.S. Food and Drug Administration. 510(k) Summary. K191379. Relizorb™. 2019 December 4. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K191379>
102. U.S. Social Security Administration (SSA). Disability Evaluation under Social Security. 105.08 Digestive System – Childhood. Available at:
http://www.ssa.gov/disability/professionals/bluebook/105.00-Digestive-Childhood.htm#105_08.
103. U.S. Social Security Administration (SSA). Program Operations Manual System (POMS). DI 24598.002. Failure to Thrive. March 2017. Available at:
<https://secure.ssa.gov/poms.nsf/lnx/0424598002>.
104. Veenendaal MV, van Abeelen AF, Painter RC, et al. Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis. *BJOG*. 2011; 118(11):1302-1313.
105. Wanden-Berghe C, Patino-Alonso MC, Galindo-Villardón P, Sanz-Valero J. Complications associated with enteral nutrition: CAFANE Study. *Nutrients*. 2019; 11(9):2041.
106. Wegrzyniak LJ, Repke JT, Ural SH. Treatment of hyperemesis gravidarum. *Rev Obstet Gynecol*. 2012; 5(2):78-84.
107. White JV, Guenter P, Jensen G, et al. Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). *JPEN J Parenter Enteral Nutr*. 2012;36(3):275-283.
108. Zangen T, Ciarla C, Zangen S, et al. Gastrointestinal motility and sensory abnormalities may contribute to food refusal in medically fragile toddlers. *J Pediatr Gastroenterol Nutr* 2003; 37:287.

Clinical Guideline Revision / History Information

Original Date: 4/11/2017

Reviewed/Revised: 1/18/2018, 4/13/2018, 4/15/2019, 07/21/2020, 04/21/2021, 12/01/2021,
03/17/2022, 3/23/2023, 12/02/2024, 05/01/2026